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Each year as cardiovascular disease continues to be one of the leading causes of death 
world wide, new treatment options are researched daily. For those whose cardiovascular 
disease progresses to end-stage heart failure, the gold standard remains transplantation. 
Those awaiting transplant however, far outweighs the available donor organs. One such 
potential to alleviate the donor shortage are decellularized cardiac scaffolds. These 
acellular scaffolds retain the native extracellular matrix and larger order branched 
vasculature. Retention of the native extracellular matrix creates an environment that is 
most optimal to support cell survival and differentiation. However, during the 
decellularization process the smaller microvasculature is mostly lost. The oxygen diffusion 
limitation in the body is around ~200 microns, and since the vast majority of tissues in the 
body are vascularized and accordingly need vascular supplies to remain viable, attention is 
turned to creating an environment that will increase the vascularization of said scaffolds. In 
order to increase said microvascular content, my dissertation study is focused on utilizing 
three angiogenic growth factors, Vascular endothelial growth factor A (VEGF-A), Platelet 
derived growth factor ββ and Angiopoietin 1 and creating a collagenous based system to 
deliver these growth factors to decellularized scaffolds and encourage vascular growth at a 
higher rate than would be seen otherwise.  
 
First, a model in vitro system was created to simulate the decellularized scaffold 
environment for testing the growth factor delivery system. This was done by using a 3D 




linked genipin. The gels were then characterized, and were seen to be able to support cell 
survival, proliferation, and even encourage trans-differentiation of human adipose derived 
stem cells towards a cardiac lineage. Then, research was focused on the testing of the 
growth factor release within a collagenous matrix. Release was found to mimic a pattern 
similar to in vivo angiogenesis over the course of 22 days. Analysis of angiogenic 
machinery, specifically the endothelial cell lumen formation complex, showed that critical 
lumen formation components were either upregulated or similar to controls, evidence that 
the presence of the growth factors do not aberrantly affect cellular behavior. Finally, 
endothelial cells were either seeded within the collagenous delivery system or on top of, 
that was then formed on top of the dECM hydrogels. Cells that had been encapsulated 
within the collagen invaded deeper into the dECM hydrogels faster than their control 
counterparts. The research done here provided the groundwork that this collagenous 
angiogenic growth factor delivery system may be used one day to increase the rate at 
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1.1 Whole Cardiac Tissue Bioscaffolds 
1.1.1 Introduction 
Cardiovascular disease continues to be the leading cause of death worldwide, with more 
patients progressing to heart failure each year [1-3]. Current treatments for heart failure are 
targeted at symptomatic improvements whereas newer investigative strategies are aimed at 
repairing injured myocardium or regenerating healthy myocardium, often via regenerative 
medicine approaches. Despite recent advancements in the field, few patients regain full 
cardiac function. Currently, the most effective treatment for patients with end-stage heart 
failure is cardiac allo-transplantation [4, 5]. However, the list of patients awaiting 
transplant far exceeds donor hearts available [6]. Therefore, developing alternative 
treatments for heart failure remains a top priority.  
 
One potential therapy is the use of a bio-scaffold to replace or support damaged cardiac 
tissue. An acellular scaffold could be applied to the surface of the heart to prevent, or even 
reverse, dilatation, or could be dosed with cells and delivered at the site of injury to aid in 
the restoration of lost cardiac cells and promote healing. Ideal scaffold candidates should 
be compatible with all cell types found in the heart, provide mechanical strength as 
location demands, guide cells to organize properly, and deliver biochemical cues for 
appropriate cell function within the heart [7]. These scaffolds may be sourced from 
biologic or synthetic materials, each of which has advantages and disadvantages.  
  
* Reprinted with permission from Springer Nature, “Whole Cardiac Tissue Bioscaffolds” by Mehta NA†, Tang-Quan KR†, LC Sampaio, DA Taylor, 2019, 
Springer Nature, United Kingdon. Copyright 2018 Nicole Mehta. † Denotes co-first authorship. https://doi.org/10.1007/978-3-319-97421-7_5 
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Synthetic materials are not always biodegradable and often lack the characteristics required 
for vascular and parenchymal cell attachment and infiltration [8], but can easily be crafted 
into virtually any size or shape.  
 
In contrast, biologic scaffolds – typically derived from extracellular matrix (ECM) – retain 
biological cues necessary for cell migration, alignment, and differentiation but can be 
difficult to obtain in a sterile reproducible fashion and generally have low mechanical 
strength for cardiovascular application. The focus of this chapter is biologic scaffolds 
derived from whole hearts, typically via removal of cells, to yield the cardiac extracellular 
matrix (ECM).  
 
In its intact state, the cardiac ECM is a complex system that contains a multitude of 
structural and non-structural proteins organized as a meshwork to hold cardiac cells 
(myocytes, fibroblasts, cardiac vascular cells, etc.) and to provide specific biological cues 
for their function.  The ECM meshwork is comprised of collagens, elastin, laminin, 
fibronectin, proteoglycans, and glycoproteins [9-12] that are arranged into two specific 
compartments: basement membrane and interstitium (Figure 1.1)[13-17]. The basement 
membrane plays a critical role in tissue function by facilitating cell-cell communication 
and organization [19]. It primarily consists of laminin and non-fibrillar type IV collagen, 
that serves as an anchor for cells and is important for cell alignment. Proper cell alignment 
is especially critical in the heart, as it is necessary both for cell-cell electrical 
communication and for productive contraction required for adequate pumping [18]. In 
contrast with the basement membrane, the interstitium is comprised of fibrillar collagens, 
elastin, various proteoglycans, and glycoproteins. It underlies the basement membrane and 
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provides mechanical rigidity to the tissue. The combined cardiac ECM creates a unique 
environment that supports multiple cell types including endothelial cells (ECs), smooth 
muscle cells (SMCs), cardiomyocytes, cardiac fibroblasts, neurons, and cardiac progenitor 
cells, in a structural arrangement sufficient for proper cardiac function.  
 
The unique architecture of the cardiac ECM is difficult to recapitulate de novo. Not only is 
the macrostructure complex, but the microstructure varies with each cardiac chamber and 
with the valves. Furthermore, the entire myocardium is thoroughly vascularized and 
contains extensive neural and electrical circuits. Building a solid organ of this complexity 
via 3-D printing, biomaterial chemistry, or other de novo methods remains difficult to date. 
Alternatively, some researchers have focused on deriving ECM-based scaffolds from 




Figure 1.1: Extracellular Matrix Compartments. (1) Interstitial matrix with fibrillar collagens, elastin, 
proteoglycans, and glycoproteins; (2) basement membrane with non-fibrillar collagens and laminin. 
Cardiomyocytes attach to the basement membrane through integrins and dystroglycan (DG). Reprinted 
with permission from [19]. 
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One technique widely under investigation to generate a cell-free scaffold with native-like 
3D architecture is perfusion decellularization of whole hearts where cells are removed, 
leaving only the cardiac ECM components. This usually involves the lysis of cells in some 
fashion (e.g. freezing, chemical perfusate) followed by vascular and chamber perfusion to 
wash out cell debris, leaving behind the ECM as a scaffold (Figure 1.2). ECM bioscaffolds 





Figure 1.2: Decellularized Porcine Heart. Decellularized porcine heart (right) adjacent to a cadaveric heart 







they can be derived from both xenogeneic sources [20] and from hearts otherwise not 
suitable for transplant; they retain the native vascular conduits and the native ECM macro- 
and micro-architecture; they preserve intrinsic biochemical cues (e.g. stereochemistry of 
the matrix, surface ligand density) that guide the alignment and orientation of cells seeded 
onto the scaffold  [21, 22]; and they can theoretically be repopulated using a recipient’s 
cells, allowing for creation of an autologous organ. 
 
The first successful perfusion decellularization of a whole heart was achieved by our group 
in 2008 [23]. We successfully showed that a rat or pig heart could be decellularized, and a 
rat heart could subsequently be partially re-cellularized, matured in vitro, or transplanted in 
vivo [23]. Since then, the decellularization of whole hearts has advanced, with new 
methods and techniques developed to decellularize and recellularize ECM bioscaffolds. 
This chapter will define the current approaches for decellularization and recellularization 













Decellularization of the heart is carried out by chemical [23-26], enzymatic [27-29], or 
physical [30] means with varying degrees of cell removal [31]. Chemical-based 
decellularization changes osmotic gradients to initiate cell membrane lysis and removal. 
Enzymatic decellularization cleaves cell membranes, cell-cell attachments, cell-ECM 
attachments, or nucleic acid ECM attachments with specific enzymes to remove cells or 
cell remnants from the organ. Physical methods of decellularization use techniques such as 
tissue freeze-thawing cycles to lyse cell membranes. Each of these is followed by a cell 
debris washout either via immersion or perfusion. Immersion involves the submersion of 
the organ, with or without agitation and then repeated solution changes to remove cellular 
debris. It can be viewed as an outside-in wash. Perfusion-based decellularization was 
developed in the Taylor lab.  It is solution-agnostic, takes advantage of the native 
vasculature or other tissue conduits, and is the method of choice for solid, whole organs 
[23, 32, 33]. In the heart, perfusion is often performed via the aorta in a fashion that allows 
full perfusion through the coronary tree.  
 
With any method of decellularization, the primary goal remains preservation of the native 
ECM composition, stiffness, and overall structure. However, each method of 
decellularization disrupts the ECM to varying degrees, and care must be taken to minimize 
ECM damage, while also eliminating cellular content. The standard for determining 
complete decellularization has been established as: 1) less than 50 ng of double stranded 
DNA (dsDNA) per mg dry weight of ECM, 2) less than 200 base pair DNA length, and 3) 
no nuclei visible upon staining using either hematoxylin and eosin (H&E) or DAPI (4’,6-
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diamidino-2-phenylindole) staining [34] garreta [35]. 
 
1.1.2.1 Chemical Decellularization 
Chemical-based decellularization reagents are primarily comprised of ionic and non-ionic 
detergents, acids and bases, and hypertonic or hypotonic solutions. These chemicals lyse 
cell membranes and wash out cellular and nuclear materials by changing osmotic gradients 
[36]. Detergent-based decellularization has been proven to be the most effective method 
for removing cellular content from many tissues but must be used at low concentrations to 
reduce the disruption to the ECM ultrastructure and preserve glycosaminoglycan (GAG) 
concentrations [37-39]. Sodium dodecyl sulfate (SDS) is one of the most widely used 
anionic detergents for cardiac scaffold generation, as it can effectively wash out 
cytoplasmic proteins and nuclear debris from the thick myocardium to a greater degree 
than other detergents [23, 40]. However, SDS can be difficult to remove from the ECM 
since it is an anionic surfactant and remains bound to ECM proteins. This leads to further 
undesired alterations in the decellularized ECM scaffold biochemistry and structure. 
Another detergent often used in conjunction with SDS is Triton X-100, a non-ionic 
detergent shown to remove cellular contents and to aid in the washout of residual SDS 
from the ECM [23, 41]. While Triton X-100 treatment results in a cell-free heart valve, it is 
less effective in clearing the myocardium and aortic wall of cellular remnants [29].  
Our group previously compared four different chemical-based decellularization techniques, 
including SDS, Triton X-100, enzymes, and polyethylene glycol. We found that a 
combination of SDS and Triton X-100 was the most effective for removing cells while 
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preserving the ECM. This technique has been successfully carried over into larger sized 
hearts, such as a porcine and human hearts [23-26, 30, 42].   
 
1.1.2.2 Enzymatic Decellularization  
Enzyme-based decellularization breaks nucleic acid bonds or cell-matrix attachments, 
which can be washed out from the native tissue. Nucleases, such as RNase and DNase, are 
used to cleave RNA and DNA into shorter strands and render the nuclei indistinguishable 
[43]. Since these nucleases target intracellular contents, they are often used alongside 
another decellularization technique, such as high pressure used in physical 
decellularization, to be effective [34]. Another common enzyme used in decellularization 
is trypsin, a serine protease that hydrolyzes proteins at the C-terminus of lysine or arginine, 
except when either is followed by proline. Trypsin is often used in cell culture to remove 
adherent cells from culture plates [44, 45]. When used in a decellularization protocol, 
trypsin cleaves peptide bonds that hold cells to the ECM. Other solutions, such as Triton 
X-100 or sodium deoxycholate, then follow the trypsin step to wash out remaining cellular 
material from the scaffold [46, 47]. Less common enzymes used in decellularization 
include collagenase, dispase, and alpha-galactosidase [34]. Just as was seen with 
detergents, enzyme concentrations that are too high or applied for too long can disrupt the 
ECM ultrastructure, strip the ECM of GAGs, and remove important glycoproteins such as 
laminin and fibronectin [41]. The balance between matrix preservation and nuclear and 




1.1.2.3 Physical Decellularization 
Multiple physical methods of decellularizing tissues have been employed such as agitation, 
freeze/thawing, and pressure application with supercritical fluids. These physical methods 
are typically followed with washing steps to remove any residual cellular debris. 
Wainwright et al. published a study that utilized freeze/thaw cycles for lysing cell 
membranes as the first step in decellularization [30][30]. After freeze/thaw cycles, a 
combination of enzymes and detergents was used to accomplish full decellularization of a 
porcine heart after only 10 hours [30][30]. The freeze/thaw method thus shortened the total 
decellularization time by lysing cell membranes prior to enzymatic and chemical 
decellularization. Another physical method is agitation, in which the whole heart is 
immersed in a decellularization reagent, followed by shaking on a mixer or a stir plate, to 
physically lyse cell membranes. Immersion decellularization of the whole heart often 
damages the external surface of the organ by the time full decellularization of inner 
constituents is achieved. Agitation helps diffuse reagents deeper into thick tissues, and in 
combination with the perfusion of the aorta, has effectively decellularized cardiac scaffolds 
[48].  
 
The application of pressure in conjunction with supercritical fluids such as CO2 that has 
already been used for smaller tissue pieces could potentially be used to decellularize whole 
organs. Supercritical CO2 has a critical temperature of 31.1°C and a pressure of 7.40 MPa, 
making it a biocompatible solution that does not require copious washing steps [49]. The 
fluid and pressure burst open cell membranes and remove cellular contents. Supercritical 
CO2 has not been applied to the whole heart yet, but its success in other tissues and smaller 
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pieces of the heart makes it a promising decellularization agent for creating whole cardiac 
bioscaffolds [50, 51].  
 
Another approach to physical-based decellularization was recently published by our group, 
where we found that inversion of a porcine heart during detergent perfusion led to lower 
DNA content, higher collagen and elastin content, and higher heart shape index (Figure 
1.3) [33]. The heart shape index was defined as the ratio of the horizontal length to the 
vertical length of the rectangle that fit the anterior-view of the decellularized hearts. Since 
higher inflow rates were necessary to maintain a pressure of 60 mmHg in the upright 
perfusion position, the inverted orientation of the heart during decellularization led to less 
aortic valve damage and improved coronary artery perfusion. Therefore, this new physical 
decellularization method appears superior to previously described methods used for 
porcine hearts [33].  
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Figure 1.3: Different Orientations of the Heart During Decellularization. Orientation affects the 
decellularization efficacy; inverted orientation (bottom) leads to higher collagen and elastin content, as 
well as aortic valve preservation. LV Left ventricle, DA descending aorta, BA brachiocephalic 





As demonstrated by the above discussion of various decellularization methods, none has 
been accepted as the field or industry standard. Currently, different groups have practices 
that differ slightly from each other. Along with different methodologies comes numerous 
values for the measure of decellularization efficacy. While most methods will leave the 
decellularized scaffold with less than 50 ng/mg of dsDNA per mg dry weight and no nuclei 
on histological analysis, the variation from heart to heart is still controversial [52]. What 
these differences mean for recellularization and eventual application of the scaffold in vivo 
has not been fully elucidated, but ongoing research is bringing about new insights into the 




Recellularization involves the seeding of vascular, parenchymal, and support cells into a 
previously decellularized scaffold. Parameters important for recellularizing the heart 
include cell type, cell concentrations, and seeding strategies. The variable cell composition 
within the heart presents a challenge when establishing the ratio of each cell type needed to 
recellularize the scaffold [53-55]. Research groups have recellularized murine and porcine 
hearts with murine or human cells, and a handful of labs have published results from 
human hearts recellularized with human cells [56, 57]. These reports employed different 
recellularization techniques: perfusion, direct injection, and a combination of perfusion and 
direct injection. This section discusses each recellularization strategy and its application in 
engineering whole cardiac tissue from decellularized ECM (dECM).  
 
1.1.3.1 Direct Injection 
The direct injection of cells into the heart involves using a syringe and needle to inject cells 
suspended in media into the area of interest. The use of a needle presents a concern that the 
ECM is damaged during the injection process. Additionally, since cells are injected into 
one specific location, and migration is often limited, cell density is not uniform throughout 
the ECM. In the first published study of a recellularized human heart, 500 million 
cardiomyocytes derived from human BJ fibroblast RNA-induced pluripotent stem cells (BJ 
RiPS) were injected using five intramyocardial direct injections between the left anterior 
descending artery and the left circumflex artery [24][24]. Upon histological analysis after 
two weeks, the 5 cm3 injection region of the tissue showed approximately 50% cell 
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repopulation, confirming that uniform cell density is still lacking after recellularization via 
direct injection [57].  
 
A shortcoming of recellularizing a scaffold via direct injection is the loss of cells during 
the injection, contributing to low numbers of cells observed in the parenchyma of the 
cardiac dECM bioscaffold in various studies [26, 57, 58]. Steps can be taken to mitigate 
the loss of cells, such as adding sutures to the sites of injection, as was done in the 
recellularization of the human heart; however, full cellularity of the parenchyma was still 
not achieved in this study. As functional cardiac tissue requires enough viable cells for gap 
junction formation and cardiomyocyte contractility in the parenchyma, it is critical to have 
complete cellular coverage in the recellularized heart. Research is ongoing to develop 
improved injection techniques for complete cell coverage of whole heart bioscaffolds.  
 
1.1.3.2 Perfusion 
Perfusion-based recellularization utilizes the native vascular conduits in the heart as a 
pathway to deliver cells. Perfusion-based recellularization is accomplished by cannulating 
one of the major vessels leading to the heart, most often the aorta, which allows for access 
to coronary arteries. Perfusion usually involves two steps: delivery of the cells where flow 
occurs, followed by a period of “rest” to allow cells to adhere. The adhesion of cells to the 
matrix is critical in all recellularization protocols but is particularly important when 
perfusion occurs shortly after delivery. If cells are not allowed sufficient time or provided 
sufficient conditions to adhere to the ECM, cells will be “washed out” of the ECM during 
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reperfusion, and incomplete recellularization will occur. This loss of cells would therefore 
result in a need for larger cell numbers for any recellularization process. 
 
In 2011, Ng et al. cannulated the aorta of a decellularized mouse heart to deliver human 
embryonic stem cells (hESCs) and human mesendodermal-cells derived from hESCs to the 
vasculature of the heart via perfusion [59]. After the heart was in static culture for 14 days, 
researchers found that the stem cells expressed endothelial cell (EC) markers in the 
vasculature, suggesting that site-specific cues were retained in the matrix and contributed 
to progenitor cell differentiation. In a similar manner, Lu et al. repopulated murine hearts 
with cells from an embryoid body, via retrograde coronary perfusion [60]. Cells then 
differentiated within the recellularized dECM into cardiomyocytes and smooth muscle 
cells (SMCs), resulting in spontaneous contractions, new vessel formation, and 
responsiveness to isoproterenol, a beta-adrenergic agonist, and E4031, an antiarrhythmic 
agent. Although contraction occurred, evidence of arrhythmias suggested the cells were 
immature and that gap junction formation between cardiomyocytes was incomplete. These 
studies provided further confirmation that the coronary vascular tree is intact after 
decellularization and can be used to deliver cells to various areas of the matrix. 
 
Due to the unidirectional flow, perfusion recellularization can result in higher cell density 
in large vessels that are proximal to the infusion site – upstream of smaller vessels. Yasui 
et al. perfused a mixture of 100 million cardiomyocytes, fibroblasts, and ECs antegrade 
through the coronary tree of a decellularized rat heart[61]. The variety of cells seeded into 
the matrix resulted in a non-homogeneous distribution of cells, with a higher concentration 
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of cells found closer to large vessels and near well-perfused vascular beds. However, 
spontaneous contractions of the heart started 2-3 days after recellularization and continued 
for the length of the 30 day culture period, suggesting that although cell distribution was 
uneven, enough cellularity was achieved through perfusion to allow the partial formation 
of gap junctions. 
 
To compare injection and perfusion side-by-side, Kitahara et al. recellularized one group of 
porcine dECM bioscaffolds by injection and a second group by perfusion, using 1.5 x 107 
porcine mesenchymal stem cells (pMSCs) in each [26]. Recellularized hearts were then 
heterotopically transplanted into recipient pigs. The perfusion-recellularized heart did not 
show patent coronary arteries during intraoperative coronary angiography, as was observed 
in the scaffold recellularized by injection. Interestingly, none of the perfused cells were 
observed in vessel lumens upon scaffold excision, while thrombi and inflammatory cells 
were evident in the parenchyma. Cells already present vs. those recruited into the 
parenchyma were not separately identified in the study. The injected pMSCs were seen in 
the parenchymal space in clusters and not homogeneously distributed. This observation 
confirmed that both methods could be used to revascularize and reseed portions of the 
cardiac dECM bioscaffolds, but both result in non-uniform distribution of cells throughout 
the matrix when compared directly. 
 
1.1.3.3 Perfusion and Injection 
Perfusion and injection is a combined approach to recellularizing the whole heart, 
delivering cells both with a needle into the parenchyma and to both parenchyma and 
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vasculature via perfusion. Our group routinely uses a combination of perfusion and 
intramyocardial injections to recellularize rat and pig hearts [23, 32]. Previously, we 
established a closed-circuit retrograde perfusion system through the aorta to infuse rat 
aortic endothelial cells (RAECs) directly into the patent aorta of a decellularized rat heart 
[23]. Histological evaluation showed adhesion of RAECs on the endocardial surface and 
within the vasculature of the heart. When five injections containing a mixture of neonatal 
cardiomyocytes, fibrocytes, ECs, and smooth muscles cells were delivered into the anterior 
left ventricle, a high degree of cell retention at injections sites was observed (>80%), 
which led to cell coupling and electrical activity propagation. By day 8, the areas of 
confluent cellularity were about 1 mm thick, and throughout the thickness of the 
ventricular wall, cell viability was greater than 95%. Although a high density of cells was 
maintained near the injection sites, density decreased with distance from the needle track.  
In another study by our group, rat hearts were re-endothelialized via three different 
methods: direct aortic perfusion of cells, perfusion of cells into the brachiocephalic artery 
(BA), or a combination of venous and arterial cell perfusions through the inferior vena 
cava (IVC) and BA; the combination of venous and arterial perfusion resulted in enhanced 
distribution of endothelial cells within the vasculature. We found that re-endothelialization 
of the heart’s vasculature by EC perfusion improved the contractility of cardiomyocytes 
injected into the myocardium [62]. This improved function is not surprising since 
endothelial cells have been previously shown to promote cardiomyocyte organization and 
survival [63]. Along with the method of delivery (injection or perfusion), the order in 




Our findings of improved cell viability and contractility from a combination of perfusion 
and injection recellularization have been confirmed in the whole porcine heart as well. In a 
study by Weymann et al., 5-6 x 106 human umbilical vein endothelial cells (HUVECs) 
were first perfused through the aorta, and then five injections of 8-9 x 106 neonatal rat 
cardiomyocytes (NRCMs) were injected intramurally into the anterior left ventricle of the 
decellularized porcine heart [64]. The recellularized porcine hearts were found to have 
platelet endothelial cell adhesion molecule-1 (PECAM-1) positive cells in the large and 
small coronary arteries, with minimal gaps in cell coverage. The seeded cardiomyocytes 
exhibited intrinsic electrical activity after 10 days in culture, but average recellularization 
of the scaffold was 50% around the sites of cell injection, and significantly decreased 
farther away from the injection sites. The electrical activity of the injected cells, as 
measured by multi-electrode array, demonstrated that areas of functionality could be 
achieved in a large whole organ, but a larger number of cells may be necessary to get 
complete cell coverage. 
 
To summarize, successful recellularization of decellularized cardiac bioscaffolds will 
require essentially recapitulating a native heart by replacing cells in the vasculature, 
parenchyma, valves, etc. This will require achieving uniform cell density in the 
parenchyma while also promoting vascularization. High cell numbers are required to 
achieve complete cell coverage, and this is especially true with larger human-sized hearts. 
While direct injection requires the insertion of a needle with a diameter large enough for 
cells to pass into the scaffold, this technique allows cells to be delivered to a specific 
location in the myocardium. Perfusion-based recellularization allows cells to reach almost 
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every part of the heart by taking advantage of the native vasculature and cavities. Order of 
cell delivery is also important, as re-endothelialization of the vasculature prior to 
parenchymal recellularization increased retention of other cell types and improved function 
of the organ [23, 32]. Additional studies are required for conclusive statements on the 




1.1.4 Clinical Applications and Potential of Cardiac ECM Bioscaffolds 
Clinical applications of decellularized whole heart scaffolds are numerous. Decellularized 
and/or recellularized matrices have the potential to replace heart valves [65], to create 
cardiac patches [66], or eventually to be used for whole heart transplantation. In fact, 
several acellular bioscaffolds have been FDA approved for use in vivo for cardiac repairs. 
However, the use of whole cardiac scaffolds is still being optimized, and several 
challenges must be addressed for in vivo applications. Figure 1.4 provides the workflow 










Thrombus formation is one of the challenges of using whole cardiac dECM in vivo. 
Animal studies have shown that fully decellularized cardiac scaffolds transplanted into a 
Figure 1.4: Workflow for Creating Functional Cardiac Tissue. Specficially, from decellularized 
bioscaffolds. Important considerations are method of decellularization, optimizing 




pig retained blood vessel diameter and shape, including the right coronary artery [26]. 
Unfortunately, these dECM scaffolds induced platelet activation, which led to 
inflammation and thrombosis formation. Incomplete endothelialization of scaffolds also 
induces thrombus formation, so complete endothelial cell coverage must be achieved for 
surfaces in contact with blood. Remnants of cellular and nuclear content in these scaffolds 
also may induce thrombus formation and inflammation. In addition, decellularization 
solutions that have not been completely rinsed out of the scaffold can prevent successful 
recellularization and engraftment into the recipient. Thorough cleaning before 
transplantation must be accomplished and standardized for decellularized scaffolds to be 
used widely in vivo. 
 
1.1.4.1 Heart Valves 
A valve homograft from a human cadaver to a human recipient is ideal for 
biocompatibility, but the shortage of organ donors is still a problem worldwide. To address 
this issue, mechanical and bioprosthetic heart valves (BHVs) have been used. BHVs from 
porcine or bovine tissue are FDA approved valves that have been sterilized and rendered 
biologically inactive by glutaraldehyde fixation [67]. One of the advantages of BHVs over 
mechanical valves is that anticoagulants are not required [68]. However, BHV calcification 
is commonly observed in patients, likely due to the glutaraldehyde-fixation process, 
increased valve stiffness, and heightened immune competence of the recipient [69]. A non-
fixed decellularized heart valve could be ideal for recipients to avoid failures associated 
with both BHVs and mechanical valves. In vivo studies of decellularized valves 
recellularized with endothelial cells and myofibroblasts showed no thrombus formation 
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when implanted into juvenile sheep [70] In some studies, decellularized valves implanted 
into sheep have also seen positive long term outcomes, where animals were alive 9 months 
post implantation with functioning valves [71, 72].  
 
Several decellularized allograft cardiac valves have already been FDA approved. 
CryoValve SG® (CryoLife Inc., Kennesaw, GA), the only approved human acellular 
pulmonary heart valve, and SynerGraft® (CryoLife Inc.) have both seen excellent long 
term success when implanted in humans [73, 74].  
 
1.1.4.2 Cardiac Patches 
A cardiac patch provides necessary support and biochemical cues for restoring cardiac 
function for diseases ranging from atrial and ventricular defects to left ventricular 
dysfunction. Cardiac patches can be generated in different ways, whether it be a 
decellularized bioscaffold, injectable gel, or a printed bioscaffold. Additionally, these 
patches may be either acellular or recellularized, sourced from non-cardiac tissues, and can 
be formed into various shapes and sizes relevant to the designed study and therapeutic 
intervention. Patches may also be from xenogeneic sources, as these scaffolds have been 
shown to be biocompatible with human cells, which allows for further patient specific 
customization due to variable wall thicknesses in different species [75]. Even without cells, 
an acellular scaffold derived from cardiac or non-cardiac tissues, can provide mechanical 
support to the failing heart, repair major blood vessels, and promote intracardiac repair.  
Bioscaffolds used for heart recovery and repair are not limited to cardiac tissues. In one 
study, acellular dermis was used to repair a left ventricular aneurysm [76]; however, cell 
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engraftment was not studied in this patient. Using urinary bladder-derived ECM, 
researchers observed spindle-shaped cells in the matrix after one month, showing a non-
cardiac derived tissue can support cardiac-shaped cells [77]. Furthermore, acellular 
scaffolds inactivated with chemical treatment still retained properties that made them a 
hospitable environment for cells [78].  
 
In other studies, components of the decellularized cardiac ECM were sufficient to cause an 
increase in regenerative capacity in vivo. In a cross-species study, zebrafish hearts were 
decellularized and lyophilized into a cardiac ECM powder [79]. This powder was 
resuspended in saline and applied to a mouse heart with a permanent ligation of the left 
anterior descending coronary artery (LAD). The results of the study were encouraging as 
the decellularized zebrafish ECM suspension could enable endogenous regeneration of the 
murine heart after acute myocardial infarction.  
 
A few of these matrices have been FDA approved and are currently used in vivo with 
positive clinical outcomes. PhotoFix® (CryoLife Inc., Kennesaw, GA), a bovine 
pericardium patch, is used for patching vascular structures and intracardiac repair [80]. 
Similarly, CorMatrix® (Aziyo, Roswell, GA), derived from porcine small intestinal 
submucosa, is used for repairing atrial and ventricular septal defects, vascular 
abnormalities, and cardiac tumors [81]. Several other matrices are also in the pipeline for 




Cardiac ECM hydrogels have recently emerged as a new technology in the field of 
regenerative medicine. These gels are created by using a novel method for retaining the 
native ECM components by turning a decellularized scaffold into a hydrogel. 
 
1.1.4.4 Injectable Gel 
The Christman group pioneered the technique for forming a hydrogel from decellularized 
porcine left ventricular myocardium [75, 82]. The majority of the dECM myocardial gel 
protocols utilize chemical detergents such as SDS or Triton X-100, while some groups 
recently have used supercritical CO2 as a method to decellularize myocardial pieces [83-
87]. After the myocardium is decellularized, it is enzymatically digested down using either 
pepsin in hydrochloric acid (HCl) or acetic acid (AA) for a period of 48-72 hours [88, 89] 
[90-92]. This digested dECM is then polymerized into a hydrogel by bringing the solution  
 
Figure 1.5: Process for the Development of Extracellular Matrix (ECM) Hydrogels. After 
decellularization, resulting tissue is lyophilized and milled into a fine powder. This powder is then added 
to a solution to form a suspension (1, top right) or digested using enzymes to form a hydrogel (2, bottom 




to physiologic pH and salt concentrations at 37°C (Figure 1.5). The mechanical strength of 
these ECM hydrogels, however, are not high (<1kPa), and several researchers have 
explored methods to increase their mechanical strength.          
 
 
 To make the ECM hydrogels stiffer, different groups have added materials such as 
chitosan, polyethylene glycol (PEG), fibrin, and silk to make a hybrid hydrogel [92, 94-
97]. These materials often bind to the matrix using photo cross-linkers to polymerize gels. 
The addition of an inert biocompatible polymer, such as PEG, into the ECM hydrogel to 
provide mechanical stiffness has been researched by the Christman group [94], where PEG 
crosslinked gels within 4 minutes and sustained a high cell viability. Addition of an inert 
biocompatible polymer is advantageous, in that the concentration of the ECM proteins is 
not disrupted, as would be for collagen or hyaluronic acid. Different groups have used 
other crosslinkers to increase the mechanical strength of these gels; for instance, genipin, a 
non-cytotoxic naturally derived chemical from gardenia fruit, has been used to render a 
hydrogel that has mechanical properties similar to native cardiac tissue [96] The hydrogels 
can also be delivered in vivo using a catheter and crosslinked in situ with positive results of 
maintained cardiac function, no induced arrhythmias, and pro-angiogenic properties when 
applied to an area of myocardial infarction [89-91, 98].  
 
Currently there are no FDA-approved ECM hydrogel products, but VentriGel™ (Ventrix, 
Inc., San Diego, CA), a myocardial ECM hydrogel derived from porcine left ventricles, is 
currently in a Phase 1 Clinical trial and is set to complete in September 2018 [99]. 
Although there are limited clinical data on cardiac ECM hydrogels, this field has a high 
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potential for growth, allowing researchers to take the lead in developing new applications 
for clinically viable therapies.  
 
1.1.4.5 Bioprinting 
3D bioprinting involves the controlled construction of an object made layer-by-layer [100]. 
This allows the user to print objects of any shape and size for a desired application. 
Bioprinting is accomplished using different printing methods such as extrusion-based, 
inkjet-based, and laser-based printing [101]. The inks used with these printers range from 
synthetic to biologic in origin, known as a “bioink”. The candidate for a bioink must 
maintain the desired shape and be able to withstand the addition of layers during the print 
process. This ink must also foster an environment suitable for cellular growth and possibly 
differentiation.  
 
ECM hydrogels have been used as bioinks for 3D printing [102, 103] and hold great 
promise, as these gels already retain in vivo ECM constituents. As a bioink, ECM 
hydrogels can support cell differentiation and survival better than traditional bioinks, 
encouraging differentiation to a specific cell type based on the tissue source [104] In a 
comparative study, rat myoblasts showed higher expression of cardiogenic differentiation 
genes when cultured on bioprinted cardiac dECM than on collagen hydrogels, showing 
evidence that the bioink retains tissue-specific cues [104] To crosslink dECM hydrogels 
for printing, different photo cross-linkers have been researched such as riboflavin (vitamin 
b2), a non-cytotoxic alternative to other photo crosslinking agents [96, 103]. Riboflavin 
with the ECM alone does not crosslink rapidly but can produce cytocompatible materials 
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with a mechanical strength similar to native cardiac ECM [102, 103] 3D bioprinting is thus 
a promising technology, as customizable structures may be created. However, an existing 
limitation is that these structures must be intricately vascularized to support complex 
tissues and organs. Further research and design development is necessary to bioprint whole 
organs with a vascular network out of ECM-derived hydrogels.  
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1.1.5 Conclusion  
Cardiac tissue bioscaffolds continue to be of great interest in the field of regenerative 
medicine due to their ability to take various forms – a whole scaffold, cardiac patch, or 
hydrogel, along with their numerous therapeutic applications for cardiovascular disease. 
New technologies such as cardiac ECM hydrogels hold promise as a potential bioink and 
as an in vivo patch; however, 3D printed structures do not innately contain vascular 
conduits, while decellularized matrices do. Decellularization of the whole heart in 2008 
paved the way for whole bioscaffolds to be used in vivo and eventually in clinical trials. As 
recellularization and other bioengineering technologies improve, the uses and applications 
of cardiac bioscaffolds continue to grow. Furthermore, for standardized manufacturing of 
these recellularized dECM matrices, guidelines must be established to manufacture 
consistently safe and effective bioscaffolds for clinical applications. Although many 
unknowns exist before whole cardiac bioscaffolds become a clinical reality, current 
research shows tremendous potential. As new discoveries happen every day, the field 











1.2 Vascularizing Decellularized Tissues  
1.2.1 Overview 
The tissue engineering of whole organs has become an expansive multi-faceted field of 
research with the goal of discovering and implementing methods to replace or regenerate 
diseased organs. The demand for organ transplant continues to increase while the donor 
lists remain steady, necessitating alternatives to traditional allogeneic transplants. The field 
encompasses research in various organ systems, each of which has a unique set of required 
parameters that must be satisfied to be successful. The common concern, which increases 
the complexity of all of these systems, is the requirement of a vascular system capable of 
supplying nutrients to the tissues. Acellular tissues are currently heavily studied as 
biocompatible scaffolds, as these tissues can potentially be recellularized with autologous 
stem cells, lowering the possibility of rejection. However, the process of decellularizing 
tissues to render them acellular often destroys microvasculature, causing the remaining 
tissue a non-viable treatment option, as the vascular content is insufficient to supply 
adequate nutrient for long-term survival. Thus, tissue engineering has begun to explore 
ways to vascularize acellular constructs to create vascular networks adequate for sufficient 
perfusion to implanted tissues.  
 
1.2.2 Introduction  
The ever-expanding field of regenerative medicine relies heavily on the development of 
biocompatible scaffolds capable of supporting cell adhesion, growth, and signaling. One of 
the most promising discoveries within regenerative medicine has been the decellularization 
of tissues and whole organs, which renders biologic matrices that are inherently compatible 
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with cells and retain the composition and ultrastructure of the extracellular matrix (ECM). 
Decellularization removes the cellular components of a tissue, leaving behind an acellular 
ECM scaffold that retains native tissue architecture [23, 62, 105-108]. This method has 
been applied to a multitude of different tissues within the body including the bladder, 
heart, trachea, liver, and kidney [62, 109-111]. The scaffold that remains after the removal 
of cellular contents may be repopulated with various cell types to create an engineered 
tissue or organ suitable for transplant. The goal is to use a transplant patient’s autologous 
stem cells to repopulate the decellularized scaffold, which might decrease the possibility of 
transplant rejection [107]. Additionally, the process of removing the cellular components 
from the scaffolds, and thus the components that cause an immunogenic response, may 
allow the use of xenografts in human organ transplants [11, 39, 112]. Due to the potential 
use of xenografts with reduced immune response, fully decellularized scaffolds may be a 
future “off the shelf” treatment for many different diseases, as tissues could be 
decellularized, stored, and re-seeded with cells as needed, increasing the availability of 
organs for transplant. Although these scaffolds seemingly provide an optimal scaffold to 
build an organ, they do not retain a vascular network that can support metabolically active 
tissues.  
 
Sufficient vascularization remains a top challenge in the successful engineering of tissues 
and whole organ replacements [40, 113-116]. While acellular scaffolds retain the network 
of vascular conduits throughout the decellularized tissue, the process of decellularization 
mostly destroys the majority of microvasculature [62]. Due to oxygen diffusion limitations 
within tissues, the absence of a dense capillary network will render the resulting implants 
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non-viable [117]. Additionally, the rate of vascular growth within the body is much slower 
than the immediate metabolic demand that a transplanted tissue requires [118, 119]. Thus, 
various methods of how to increase the vascular content within decellularized scaffolds is a 
focus of current research.  
  
Vascularization of decellularized scaffolds poses two different challenges; the acellular 
scaffold must: 1) be fully re-endothelialized, and 2) promote outgrowth of new vascular 
structures from the existing ones to increase the density. To encourage neovascularization 
within decellularized scaffolds different methodologies that have been implemented 








Figure 1.6: Angiogenesis vs. Vasculogenesis. Angiogenesis (right), the outgrowth of new vessels 
from existing vessels, and Vasculogenesis (left), the growth of new vasculature from 
progenitor/stem cells.  
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including cell types known to encourage vascular growth such as endothelial cells or 
fibroblasts, bolus injections of growth factors into specific areas, and encapsulation of 
angiogenic growth factors into hydrogels. All of these methods aim to re-endothelialize the 
scaffolds, and increase the rate of neovascular growth (Figure 1.6). The following review 
will summarize various methods that are currently employed to encourage re-
endothelialization and subsequently encourage vascular growth, as well as provide insight 
into the state of the field of regenerative medicine where the future of the field is.  
 
1.2.3 Re-endothelialization of Acellular Scaffolds  
As the decellularized scaffold retains the majority of the vascular architecture, the main 
technique that has been used to encourage vascular growth in these constructs has been 
seeding these scaffolds with endothelial cells (ECs); known as re-endothelialzation. The 
vasculature of decellularized scaffolds must be seeded with ECs, as scaffolds without the 
presence of ECs have been shown to be leaky and thrombogenic [62]. Additionally, 
complete cell coverage of the vessels is necessary in order to replicate the function of the 
endothelium in vivo. There are multiple cell types that may be utilized in the re-
endothelialization of the vasculature, with each cell type having different efficacy on the 
regrowth of functional vessels.  Elucidating the optimal cell type for re-endothelialization 
that can encourage the growth of new vessels as well as provide complete endothelial 
coverage of vessels is critical and necessary for a functional vascular network. 
Additionally, research should be conducted regarding the supporting cell types present in a 
vessel such as pericytes, as they play an important role in the vessels as a producer of 
growth factors and as a regulator of capillary blood flow [120]. 
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1.2.3.1 Stem Cells 
 Stem cells may be an optimal cell source to vascularize a decellularized matrix due to their 
capacity for self-renewal and ability to differentiate into multiple cell types. These cells 
can either be differentiated by in vitro exogenous growth factors, or in situ by both growth 
factors and signals from the ECM.  Stem cells have been used in engineering tissues such 
as decellularized kidneys, in which embryonic stem cells were shown to differentiate into 
ECs within the remnant vascular architecture [22]. In the study by Ross et al., murine 
embryonic stem cells were injected into an arterial cannula within acellular scaffolds, with 
no added growth factors into the media. Scaffolds were then sectioned and stained positive 
for an EC specific lectin, BsLB4 and vascular endothelial growth factor receptor 2 
(VEGFR2) [121]. BsLB4 is an EC specific lectin that is used as an indicator of EC 
differentiation [122]. The VEGFR2 is a receptor specific to vascular endothelial growth 
factor (VEGF), and is primarily expressed on vascular EC surfaces and significant in 
angiogenesis [123].  The presence of these signals were found to be most apparent within 
the vasculature and glomeruli in the kidneys, indicating that the embryonic stem cells were 
not only differentiating into ECs but also differentiating in areas where vasculature had 
previously been. Investigators believe that the cells differentiated in the correct location 
due to the retention of site-specific signals within a decellularized matrix [22]. In a 
separate study conducted by Lu et al., induced pluripotent stem cells (iPSCs) were 
differentiated into cardiomyocytes, smooth muscle cells, and ECs, which were 
subsequently used to repopulate decellularized mouse hearts [124]. Through a cannulated 
aorta, iPSCs were perfused through the heart. After 7 days, vessel-like structures were seen 
within these re-cellularized hearts, indicative of cell differentiation into ECs [27]. These 
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results indicated that one stem cell type could differentiate into smooth muscle cells, 
cardiomyocytes, and ECs. The findings from Lu et al. provided further evidence that the 
ECM niche within an acellular scaffold retains the cues necessary to promote cell 
differentiation. The use of iPSCs as a cell source for regenerative medicine holds 
tremendous promise, as these cells could in the future be autologously derived, and 
differentiate into various cell types. Despite the promising ability to direct iPSCs into any 
cell type, iPSCs are cultured at a low rate, and require increased time to produce an 
adequate amount that would be needed to sufficiently re-endothelialize a scaffold [125]. As 
we have previously reported, stem cells are more resistant to hypoxia than cells that have 
differentiated further, potentially allowing higher survival rates in an environment such as 
a decellularized matrix [62, 126]. However, these cells also have the risk to become 
tumorigenic due to transgene insertion [127]. Although stem cells have promising 
characteristics as a cell source for the re-endothelialization and the subsequent vascular 
growth of scaffolds, they still need to be directed into differentiating into the EC lineage, 
adding a layer of complication.  
 
1.2.3.2 Endothelial Progenitor Cells 
Endothelial progenitor cells (EPCs) can be sourced from peripheral blood, adipose tissue, 
and bone marrow [128, 129]. EPCs are involved in the creation of new vessels in vivo, the 
expansion of existing vessels, and additionally have the capability to form new vessels in 
vitro [128, 130]. Using EPCs for re-endothelialization of the decellularized tissues has 
shown to repopulate the vasculature and form vessels similar to the native tissues in organs 
such as liver, heart, bladder, and kidney [110, 129, 131].  In a study of adipose derived 
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endothelial progenitor cells (ADEPCs) on their angiogenic potential within decellularized 
bladder scaffolds, Dai et al., found that the ADEPCs showed EC like characteristics 
through the expression of cell markers such as CD31 and eNOS [132]. Additionally, these 
cells (ADEPCs) could form capillary-like structures within Matrigel, indicating their 
angiogenic capability, from a potential autologous source [129]. Bone marrow derived 
endothelial progenitor cells have also been used to re-endothelialize a liver scaffold [129]. 
EPCs were seeded into the liver scaffold via the portal vein and cultured for 3 days before 
being analyzed. Scaffolds stained positively for CD31, and a cross section of the 
vasculature showed that ECs had covered the vessel structures [129]. Authors did note, 
however, that the re-endothelialization was seen more in the larger vessels versus the 
smaller vessels, and hypothesized that this was due to differences in media pressure 
gradients. In a study conducted by Maniu et al., Wharton’s jelly mesenchymal stem cells 
(MSCs), were differentiated into EPCs through exposure to different growth factors such 
as VEGF, IGF, EGF, and bFGF, and cultured for 4 weeks. Cells were then analyzed for EC 
cell markers, CD31, CD105, as well as EPC cell markers CD34, and CD133, all indicative 
of EPC differentiation [133]. Additionally, they also exhibited decreased expression of 
MSC marker CD90, further indication of MSC to EPC differentiation. EPCs were then 
seeded onto a decellularized umbilical cord section and cultured for 4 days. EPCs were 
shown to successfully integrate into the decellularized human umbilical cord vein, lining 
the vessel. These results showed that the Whartons jelly derived EPCs could be a potential 
source of ECs for reendothelialization of a decellularized tissue [133]. The ability to 
differentiate MSCs into EPCs would allow EPCs to be obtained more easily, as they could 
be derived from adipose tissue, and in greater numbers.  
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An advantage of utilizing progenitor cells is that these cells are closer to full differentiation 
of a particular lineage, potentially eliminating the possibility of trans-differentiation. These 
cells could also be autologously derived, potentially decreasing a host immune response. 
However, although isolation from peripheral blood is possible, the circulating numbers of 
EPCs are low, so sufficient growth is difficult.  While the EPC has shown to successfully 
endothelialize a scaffold, as well as grow vasculature, the difficulty in isolation of these 
cells from the blood could potentially prove to be a major deterrent as the larger use of this 
cell might be impractical. However, the promising studies indicating that WJ-EPCs and 
adipose derived EPCs are a potential EC source, lead to the possibility of these cells being 
useful endothelialization candidates. There is, however, limited information and further 
studies must be performed on the long-term capabilities and angiogenic potential of the 
EPC in a recellularized scaffold.  
 
1.2.3.3 Adult Endothelial Cells 
Adult Endothelial cells have been used to re-endothelialize many decellularized tissues. As 
our previous work has shown, rat aortic endothelial cells (RAECs) infused into the 
vasculature through both venous and arterial ends of a rat heart can repopulate the vessels 
and decrease the incidence of thrombus formation [62]. Human umbilical vein endothelial 
cells (HUVECs) have been used to repopulate rat acellular kidneys [1]. While these 
HUVECS were shown to repopulate the vasculature, the vascular resistance was high 
compared to native vessels, potentially due to a lack of a mature vessel structure [134]. 
Although the risk of differentiation in committed cell lineages are lower, they also have the 
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capacity to enter senescence sooner than stem cells, and may have a decreased ability to 
proliferate at rates similar to stem cells.  
 
1.2.3.4 Co-Seeding of Cells 
The co-seeding of ECs with other vascular cells, such as smooth muscle cells (SMCs), into 
a decellularized matrix can help recapitulate the native vascular environment more 
accurately. The co-seeding of these cells have been shown to facilitate growth of neo-
vasculature at significantly higher levels compared to ECs alone in tissues such as 
decellularized small intestinal mucosa [135]. The rationale for the co-seeding of these cells 
is that the SMCs will differentiate into the smooth muscle that normally surrounds the 
vasculature. The co-culture of cells has also been shown to increase vascular density in a 
study by Sarig et al. in which hMSCs were co-cultured with HUVECs and found that ECs 
tended to proliferate in areas where the hMSCs were differentiating into supporting 
vascular cells [40]. The presence of the hMSCs greatly increased the amount of capillary 
growth [40]. An advantage of seeding scaffolds with ECs in addition to other cell types is 
that these support cells (smooth muscle cells) will secrete additional angiogenic growth 
factors that will directly influence the ECs. This will lead to the continued production of 
growth factors and would provide the micro environmental cues necessary for continued 
growth of mature vasculature, and rapid host integration.   
 
The determination of the correct cell type for re-endothelialization remains a challenge. 
The acellular lumen must have full cellular coverage, otherwise vessels become leaky and 
thrombogenic. Many factors must be taken into consideration when determining the most 
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optimal cell type. To re-endothelialize a scaffold requires a large amount of cells, and often 
there is low cell adherence, which must be taken into account. Additionally, the source of 
the cells is crucial for prevention of an adverse immune response and potential graft 
rejection. Unfortunately, the seeding of cells alone thus far has not proven to grow a 
vasculature that is dense enough to support the tissue. The vascular lumens must be re-
endothelialized, and then rapidly grow additional microvasculature and anastomose with a 
host vasculature in order to survive. Because of this, in conjunction with delivery of the 
cells, different methodologies to deliver different angiogenic cues have been explored, to 
help encourage the rate of vascular growth in decellularized tissues.  
 
1.2.4. Bioactive Molecule Delivery  
Bioactive molecules such as angiogenic growth factors (GFs) are signaling molecules that 
influence ECs to grow new vasculature. These GFs may be delivered to cells in different 
ways; by physically being bound to the matrix, using a hydrogel, using microparticles, or 
in a single bolus delivery (Figure 1.7). The bolus delivery of GFs refers to the 
perfusion/injection/delivery of GFs all at one time, without any temporal control in the 
way of delivery and can result in quick degradation of the GFs [136]. Multiple growth 
factors may be delivered at once with this method, or staggered throughout the time of cell 
culture. With uncontrolled delivery of growth factors into an acellular matrix, there is a 
potential for inconsistent dosage to certain areas of matrix, which could lead to non-
uniform cellular growth [137]. Additionally, the over dosage of certain growth factors 
could have detrimental effects to a scaffold and surrounding tissues. Finally, many growth 
factors have a short half-life, resulting in even further reduction of the GF efficacy [138]. 
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In order to use GFs efficiently, they must be delivered in a fashion that allows for cellular 
exposure in a controlled manner that leads to consistent dosage, and controlled timing. 
Below, we discuss different ways GFs are being used to encourage neovessel growth in 






1.2.4.1 Matrix Based Delivery 
Matrix based delivery of bioactive molecules refers to the physical attachment/ 
encapsulation of a GF to the matrix itself. This may be beneficial, as it may lead to the 
sustained release of a GF over time, as cells are exposed to the GFs as they invade the 
matrix. In a study by Ogawa et al., they tested the incorporation of single growth factor, 
Scaffold with bioactive molecules and 
vascular ingrowth
Scaffold with bioactive molecules
Figure 1.7: Bioactive Molecule Delivery in Scaffolds. Left, Scaffold with encapsulated or chemically 
bound bioactive molecules. Right, vessel ingrowth into the scaffold from the influence of the 
bioactive molecules.  
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basic fibroblast growth factor (bFGF), into the matrix, by rehydrating a lyophilized bladder 
acellular matrix (BAM) with the GF. The group saw an increased density of vasculature 
the bFGF BAM when incorporated into murine subcutis, compared to controls [109]. Dai 
et al. continued studying the BAM, specifically the effects of the addition of VEGF and 
platelet derived growth factor BB (PDGF-BB). On the BAM, lyophilized matrices were 
rehydrated with GFs and incubated for 12 hours prior to implantation into a rabbits with 
partially resected bladders [139]. The experimental groups (with GFs) showed significantly 
more vascular structures with greater vessel cross sectional area than control groups. 
Interestingly, the group noted that there was increased vessel growth in the outer regions of 
the patches that did not extend to the inner areas of the patches. They hypothesized that 
this was due to the slow rate of host vascular ingrowth [139]. Loai et al. investigated the 
incorporation of VEGF at varying concentrations into a BAM, with the addition of 
hyaluronic acid (HA) [140]. The group looked at the implantation of a BAM with 
BAM+VEGF+HA, only HA, and only a BAM into a portion of a porcine bladder. After 
both 4 and 10 weeks, the BAM+VEGF+HA group was seen to have the highest amount of 
recellularization compared to the other groups. Additionally, they saw an increase in the 
amount of CD31+ (a marker of vasculature) staining present in the BAM+VEGF+HA 
group. They found that there was evidence of increased angiogenesis within VEGF 
containing scaffolds, and that the presence of hyaluronic acid increased the amount of 
CD31+ vessel density, compared to scaffolds without VEGF [140]. In a study conducted 
by Hilfiker et al., a portion of a porcine small intestine was decellularized to form a 
biological vascularized matrix (BioVaM) [141]. The matrix segment was then coated with 
a matrix-associated protein CCN1 a protein that has been shown to promote adhesion, 
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migration, and proliferation of ECs [38]. The CCN1 was attached to the matrices by 
perfusing 100 ng/ml of the protein through the BioVaM, and subsequently removing the 
unbound CCN1 after overnight incubation. Human cord blood endothelial cells (hCBEC) 
were used and perfused into the BioVaM structures, and incubated and cultivated for 4 
days [38]. The group noted that compared to the BioVaM structures that did not have the 
CCN1, the matrices showed an increase in the adhesion of the hCBEC, and retention. 
Additionally, authors found that there were longer vessel structures seen in the CCN1 
groups, as well as seeding wide interconnected vascular structures after 14 days in culture, 
compared to the non-CCN1 groups. The group believes that part of the increased adhesion 
of the hCBEC arises from the integrin binding of CCN1 and the cells [38]. It is noted that 
there was not complete re-endothelialization within these scaffolds after 14 days in culture. 
Further study must be conducted on this system, as well as perhaps the inclusion of an 
additional signaling molecule. 
 
1.2.4.2 Hydrogel Based Growth Factor Delivery  
Hydrogels are hydrophilic polymeric materials that have been widely used in the field of 
tissue engineering [142, 143]. These polymeric materials have the ability to retain large 
amounts of water due to their hydrophilic nature [142-144]. Hydrogels can be made with 
either biologic or synthetic materials, and are often biocompatible [142]. Naturally derived 
hydrogels are especially attractive as these retain the properties most similar to the ECM, 
are biocompatible, and biodegradable [143, 144]. The biodegradability of a naturally 
derived hydrogel enables the possibility of using hydrogels as a bioactive molecule release 
mechanism, which has been widely used [143]. The porosity and release rate of a bioactive 
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molecule can be manipulated by altering densities of these materials, as needed for each 
application [143]. These characteristics of hydrogels render them a tool to encapsulate 
bioactive molecules such as angiogenic GFs, to be used for tissue engineering purposes. 
The application of hydrogels in decellularized tissues has been mostly limited, but has 
been widely studied in other tissue engineering applications. In a study performed by 
Kanematsu et al., collagen was chosen as a GF delivery vehicle, and hepatocyte growth 
factor (HGF), PDGF-BB, VEGF, insulin like growth factor-1 (IGF-1) and heparin binding 
epidermal growth factor (HB-EGF) were incorporated into the scaffold [137]. The 
researchers found that there was an initial large release of growth factors from the scaffolds 
as measured by radioactive tagging, and then sustained release of the growth factors for a 
period of up to 30 days, depending on the growth factor. Additionally, the matrix itself was 
shown to be degrading at rates that were similar to matrix degradation rates [137].  
 
Although hydrogels have beneficial characteristics that may make them ideal candidates 
for growth factor delivery to decellularized tissues, there has been limited application and 
more research must be completed in order to determine the efficacy of delivery with a 
hydrogel.  
 
1.2.4.3 Particle Based Growth Factor Delivery  
The encapsulation of growth factors within micro- or nanoparticles enables the spatial and 
temporal controlled release of the growth factors into scaffolds, and has been used in 
different tissue engineering applications. Particles that are made out of biodegradable 
materials are ideal, as the body’s rate of degradation would translate to rate of molecule 
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release. These micro- or nanoparticles can lead to longer sustained release of bioactive 
molecules, compared to a molecule directly added into the matrix. Particles may be 
synthesized from various synthetic materials, such as poly (lactic-co-glycolic acid) 
(PLGA), or natural materials such as alginate or chitosan [145-147]. Synthetic materials 
can be beneficial as they are easily obtained and manipulated, but natural biomaterials may 
elicit a decreased immune reaction.  
 
Geng et al. loaded PLGA nanoparticles with VEGF, and injected them into BAMs, which 
were then implanted into porcine bladders. At weeks 4 and 12 post injection, there were 
significantly higher densities of micro-vessels within bladders containing nanoparticles 
compared to the control groups, as shown by CD31 positive structures [147]. Additionally, 
they saw sustained VEGF release that lasted for up to 3 months [45]. The authors also 
noted that with the incorporation of their particles, they saw less contraction of the 
implanted bladder. The contraction of implanted segments is not ideal, as it changes the 
structure and potentially function of an implanted graft.  
 
Heparin is a linear polysaccharide that has been used in conjunction with a variety of 
bioactive molecules due to its ability to bind and prevent degradation of growth factors 
[148-150]. Heparin can also adsorb to the matrix surface. In a study by Wu et al., heparin 
was used in conjunction with Chitosan, a natural biomaterial, to form nanoparticles that 
were immobilized onto a decellularized bovine jugular vein [44]. VEGF was then 
complexed to these scaffolds, by VEGF binding to the heparin/chitosan particles within the 
bovine jugular vein scaffold.  
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Capillary density was shown to significantly increase within scaffolds with VEGF 
incorporated nanoparticles in vitro and in vivo [148]. Wu also noted that in vivo, the 
vasculature that grew from the scaffolds appeared to aggregate with the tissues surrounding 
the implant, suggesting they anastomosed with host vasculature.  
 
A unique possibility with particles is the ability to administer more than one bioactive 
molecule at a time, and at different times. These could be customized to create an 
environment more suitable for growth of more mature vessels, as it could be made to 
mimic angiogenic signaling patterns [147]. Particles have been previously made by 
Mooney et al. to deliver multiple GFs in a sequential manner in a collagen scaffold. The 
group worked on the co-administration of fibroblast growth factor (FGF) and angiopoietin-
1 (Ang1), two growth factors important in angiogenesis and the stabilization of vessels 
[151, 152]. This enables the early release of factors that initiate the growth of vessels, 
followed by the release of factors that encourage maturation and long-term stabilization of 
vessels. The application of particle based molecule release in decellularized scaffolds 
needs to be further researched. In particular, particles made out of existing ECM material 
may be an especially promising category.  
 
1.2.5 Conclusions and Future Directions  
Using the native tissue architecture of a decellularized organ and repopulating the 
vasculature of the scaffold while encouraging neovascular growth holds promise of being 
the most clinically translatable method to create a vascularized tissue engineered construct. 
Because these scaffolds retain existing vascular architecture, when used in vivo dECM 
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scaffolds may anastomose with the host’s vasculature more effectively. However, 
encouraging neovascular growth is the rate-limiting step to creating a viable tissue 
engineered construct. While steps have been made and different techniques have been 
developed, there has still not been a scaffold made with an adequate amount of vasculature 
for immediate use. Many different systems have been utilized to help encourage growth of 
vasculature in the matrices, but each is associated with advantages and disadvantages. The 
recapitulations of the angiogenic processes are difficult, as these are complex in vivo 
signaling processes. In order to replicate these processes, angiogenic growth factors should 
be delivered to the scaffolds in a sequential, temporally controlled manner to mimic in vivo 
angiogenesis signaling and theoretically leading to the growth of more vascular structures. 
In addition to using the most optimal cell type, a method to deliver angiogenic molecules 
using a material such as a hydrogel, could potentially be a promising way to re-
endothelialize and encourage new vascular growth from a decellularized scaffold. Because 
of the ability to customize a hydrogel to a desired release profile, bioactive molecules 
could be delivered in a fashion that could help encourage sustained vessel growth. 
Scaffolds could also be pre-vascularized in this manner, lessening the amount of time 
required to provide a patient with an “off the shelf” tissue. There has been extensive 
research performed in hydrogel-based growth factor delivery in tissue engineering, but 
limited application in the field of decellularized tissues.  Further research is necessary to 







2 CARDIAC DECELLULARIZED EXTRACELLULAR MATRIX UNIQUELY 
AFFECTS STEM CELL DIFFERENTIATION 
 
2.1 Overview  
As cardiovascular disease, including myocardial infarctions, continues to be the leading 
cause of death worldwide therapeutic interventions aim to reinforce or replace injured 
myocardium to regain the contractile function of the tissue. One approach is by using a 
cardiac patch, placed in areas of damaged myocardium to act as a mechanical support. In 
this study, we explored how a candidate cardiac patch material, cardiac decellularized 
extracellular matrix (dECM) hydrogels, are affected by changing cardiac dECM hydrogel 
formation, and how these changes affect the resulting hydrogel and consequently cell 
behavior.   
 
To accomplish this, dECM was enzymatically digested for increasing amounts of time (24 
- 72 hours) and crosslinked with genipin to form hydrogels with a range of mechanical 
properties. Time to gelation, material elasticity, and enzymatic degradation were 
quantified; hydrogels formed from dECM solutions enzymatically digested for 24 hours 
formed gels faster, were stiffer, and degraded at a slower rate. Biocompatibility was 
assessed by maintaining human cardiomyocytes, umbilical vein endothelial cells, and 
cardiac fibroblasts, on the hydrogel formulations. Finally, the effect of dECM on human 
adipose derived stem cell differentiation down a cardiac lineage was evaluated, including 
the roles of the β4 and β5 integrin subunits.  Gels formed from dECM solutions digested 
for 24 hours increased cardiomyocyte-specific gene expression compared to dECM with 
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longer digestion times. Our study provides further evidence that tissue specific dECM 
hydrogels retain tissue specific cues that promote differentiation of stem cells, and may be 
suitable to stimulate stem cell differentiation and vascularization within a cardiac patch. 
 
2.2 Introduction 
Available treatment options for cardiovascular disease vary from drug therapy, 
interventional devices, and if necessary, transplantation [153]. One of the leading and most 
debilitating causes of heart failure stems from myocardial infarction (MI). Acute MI results 
from a loss of blood flow, and the accompanying oxygen, to an area of the heart, causing 
that area to become ischemic [154]. If perfusion is not restored within the first few hours, 
the often irreversible tissue damage leads to cell necrosis and causes an inflammatory 
reaction in the surrounding tissues which can induce further injury and affect the function 
of non-ischemic myocytes [155, 156]. This progressive degradation leads to deterioration 
of cardiac function and eventual heart failure [156]. Current treatment options for heart 
failure include pharmacologic interventions, cardiac resynchronization therapies, surgical 
interventions, and mechanical circulatory support (left ventricular assist devices; LVADs) 
[157-160]. Mechanical circulatory support is used to offload either the left or the right 
ventricle, and can be used as a bridge to transplant, or a bridge to recovery in certain cases 
[161]. It can also, however, cause serious complications such as pump thrombosis, stroke, 
and infection [158], [162], [163]. The large majority of patients with heart failure continue 
to decline despite therapeutic interventions [164, 165]. Currently, the most effective 
treatment for patients in end-stage heart failure remains a heart transplant; however, the list 
of recipients in need far exceeds donor organ availability [6, 158, 160]. 
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Alternative newer regenerative medicine based treatments for heart failure include the 
application of cardiac patches to a localized area of damage in order to halt the progression 
of heart failure [166]. These tissue engineered cardiac structures reinforce the area 
damaged by ischemia with the aim of preventing further decline, while also promoting 
angiogenesis [40]. Different approaches have been proposed for the design of cardiac 
patches, including both biologic and synthetic materials [66, 167]. Ideally, these patches 
should mimic cardiac tissues as closely as possible in their mechanical properties, 
biochemical composition, and biocompatibility. The complex structure of the myocardium 
is challenging to engineer ex vivo, and thus acellular myocardial scaffolds have become an 
increasingly popular option in cardiac tissue engineering [11, 19, 23, 30, 62, 66, 168-173]. 
 
Acellular cardiac scaffolds can be derived from cadaveric human, pig, rabbit, or rat donor 
hearts [23]. The decellularization process removes cellular components from the tissue 
scaffold, leaving crucial acellular protein matrix scaffold behind [23, 40, 174] and 
significantly decreasing the possibility of immunogenic reactions [175]. The ECM 
components that remain can serve as a scaffold for cell attachment, proliferation, and 
migration [176]. Depending on the processing of the matrix, the scaffold may be used to 
provide stable mechanical support to maintain the architectural elements of the original 
tissue or can serve as an injectable therapy to be applied directly to the site of damaged 
tissue [113, 169-171]. These decellularized ECM (dECM) scaffolds retain the complex, 
tissue-specific mixtures of proteins and polysaccharides that guide cellular behavior and 
thus provide an enhanced microenvironment compared to purified protein scaffolds formed 
from collagen and fibrin [11, 34, 169, 176-178]. In 2008, our laboratory successfully 
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pioneered the use of perfusion to decellularize a whole organ [23], and we demonstrated 
successful recellularization of rat hearts that could be transplanted in vivo [62]. Since then, 
the field of decellularization has expanded and encompasses not only whole organs, but 
also dissected tissues that are further processed into powders or particles. These products 
have been reconstituted into various types of biomaterials [75, 179-182], including dECM 
hydrogels [35, 84, 88, 103, 183-186].  
 
Myocardial matrix hydrogels, derived from decellularized left ventricular myocardium, can 
be formed under physiologic conditions through the self-assembly of matrix proteins. 
These hydrogels have been shown to be bioactive and improve cardiac function in both rat 
and porcine models of MI [75, 88, 187]. The tailoring of material properties such as 
mechanical stiffness, degradation profiles, and hydrogel composition can extend the range 
of potential biomaterial applications. Both physical (UV light) and chemical 
(carbodiimides, glutaraldehyde) crosslinking methods have been used to increase the 
mechanical stiffness of ECM-based biomaterials [103, 188-190]. Recent work has also 
shown that genipin, a naturally derived iridoid derivative found in the fruit of the gardenia 
(Gardenia jasminoides) [191-199] is a less cytotoxic crosslinker for various biologic-based 
scaffolds including chitosan [199-202], chondroitin sulfate [191], collagen [193, 196-198], 
gelatin [203], dECM [195, 204, 205], and hybrids of dECM with other materials [96]. 
Studies have also demonstrated that genipin-crosslinked scaffolds have improved 
mechanical properties and tunable enzymatic degradation profiles compared to non-




The exact composition and structure of the ECM is tissue-specific and varies due to the 
evolving cellular and environmental cues present during tissue development. The protein 
composition of the ECM has been shown to mediate several cellular processes such as 
adhesion, proliferation and differentiation [206]. In particular, collagen, fibronectin, and 
laminin have been implicated in significant roles during cardiac differentiation, and 
integrin subunits that predominantly interact with these three proteins, β1, are most highly 
expressed in cardiomyocytes [207, 208]. Integrins are heterodimeric membrane 
glycoproteins comprised of α and β subunits, which bind and recognize ECM proteins. 
Bidirectional integrin signaling influences both intracellular activity and extracellular 
affinity for ECM ligands [15]; however, the exact cues necessary to direct stem cell fate 
are not easily identified due to the complexity of the native cell environment [206]. 
Previous studies have shown that specific integrins, such as the β1 subunit and it’s 
associated α subunits, are key facilitators of cardiac cell differentiation [207, 209, 210], 
[206, 211], and that the inhibition of other β subunits increases the activity of β1 integrins 
[212]. Thus, in our current study, I utilize decellularized porcine myocardium hydrogels to 
investigate two major factors that influence mesenchymal stem cell differentiation: 1) 
ECM protein and peptide composition, and 2) β1 integrin activity. I hypothesize that 
alterations in hydrogel protein content, achieved by variations in the enzymatic digestion 
of dECM would lead to crosslinked matrices of similar mechanical properties, but distinct 
environmental cues. dECM was digested over a range of different time courses following 
decellularization and the resulting digests were crosslinked with varying amounts of 
genipin. The mechanical properties and enzymatic degradation rates were assessed, as was 
the ability of these crosslinked hydrogels to sustain cardiac cell adhesion, viability, and 
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proliferation, and to guide mesenchymal stem cell differentiation toward a cardiac lineage. 
The impact of increased β1 integrin activity was assessed through the inhibition of β4 and 
β5 integrin-mediated activity. The data presented herein is intended to further explore the 
utility of crosslinked cardiac matrix as a suitable microenvironment for cardiac 
differentiation and an eventual scaffold for cardiac repair. 
 
2.3 Specific Aims  
Specific Aim 1: Create a 3D dECM hydrogel to be used as an in vitro model to simulate in 
vivo conditions.  
Specific Aim 1.1: Create hydrogels made out of porcine left ventricular decellularized 
extracellular matrix of dECM and characterize the material made. I hypothesize that the 
digestion of the dECM will affect the material strength and cell behavior of the resulting 
hydrogels, such that an increased about of digestion time will aberrantly affect cell 
behavior and increase material strength.  
Specific Aim 1.2: Characterize the effect of increasing digestion time on stem cell 
behavior and differentiation. I hypothesize that adipose derived stem cells will express 
cardiac markers on all dECM hydrogels regardless of the length of digestion times, but that 
the increasing digestion time will lead to a decrease in expression of cardiac genes.  
Specific Aim 1.3: Elucidate the effect that the material composition has on the 
differentiation of adipose derived stem cells towards a cardiac phenotype. I hypothesize 
that by blocking the integrins beta 4 and beta 5, known fibronection and laminin receptors, 
the expression of cardiac genes will decrease since fibronectin and laminin have been 
implicated in cardiac differentiation.  
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Overall Goal for Specific Aim 1: Create a 3D environment of decellularized extracellular 
matrix that can be used to validate my system to be created in Aim 2 to increase 
vascularization in a decellularized environment.  
 
2.4 Materials and Methods  
All chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise 
indicated. 
2.4.1 Cardiac dECM Preparation 
Porcine hearts were obtained from a USDA certified slaughterhouse (K&C Processing, 
Navasota, Texas). Left ventricular (LV) free wall tissue was excised and rinsed in 
deionized (DI) water. Tissue samples were then trimmed to remove residual chordae 
tendinae, valve leaflets, papillary muscles, adipose tissue and, most epicardial surfaces 
from the exterior portion, leaving primarily LV myocardium. Sections were either frozen at 
-20°C in sterile phosphate buffered saline (PBS) or decellularized immediately. For 
decellularization, LV wall sections were cut into small pieces approximately 36 - 64 mm3 
(Fig. 2.1A), which were then suspended in a hypertonic 500 mM sodium chloride (NaCl) 
solution for 2 h at 500 rpm. Samples were filtered using a sterilized fine mesh metal filter 
then transferred into a hypotonic 20 mM NaCl solution for 2 h at 500 rpm, followed by 
another filtration. Tissues were subsequently exposed to a 1% sodium dodecyl sulfate 
(SDS solution in PBS containing 2500 U of penicillin/streptomycin (Thermo Fisher, 
Waltham, MA), then stirred at 500 rpm for 24 h. Solutions were changed every 24 h for a 
period of 5 days until the solutions remained clear and the tissue took on the characteristic 
opaque appearance of decellularized cardiac matrix (Fig. 2.1B). The dECM was rinsed 
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several times with water to ensure SDS removal, then exposed to a 1 kU/ml solution of 
DNAse in DI water for 2 h. After additional rinsing with DI water, the dECM was frozen 
to -20°C, lyophilized, and pulverized with a mortar and pestle. The resulting dECM 
powder was digested with pepsin (1 mg/ml) in 0.1 M hydrogen chloride (HCl) for either 24 
h, 48 h, or 72 h, at which point the product was neutralized to pH 7.4 and stored at -20°C 
until use. 
 
2.4.2 DNA Quantification 
Residual double-stranded DNA (dsDNA) in dECM samples was quantified using Hoechst 
33258 (Molecular Probes, Eugene, OR), which emits blue fluorescence when bound to 
dsDNA. dECM samples of approximately 20 mg each were analyzed for DNA content 
prior to freezing and lyophilization in order to gauge the efficiency of the SDS-mediated 
decellularization process. dsDNA content of dECM samples was compared to that of fresh 
tissue samples harvested from the same organ. Prior to the assay, samples were digested at 
55°C overnight in a 10% solution of proteinase K in PureLink Genomic Digestion buffer 
(PureLink Genomic DNA Mini Kit; Invitrogen, Carlsbad, CA). Following digestion, a 
phenol-chloroform extraction was used to recover dsDNA. Briefly, samples were diluted in 
10 M Trizma hydrochloride (Tris HCl, pH 8.5) and mixed with a 25:24:1 solution of 
phenol/chloroform/isoamyl alcohol. After subsequent mixing and centrifugation, the top 
(aqueous) layer was recovered and the bottom layer was subjected to an additional dilution, 
mixing, and centrifugation to recover any remaining dsDNA. The recovered aqueous 
solution was further diluted in an equivalent volume of a 24:1 mixture of chloroform and 
isoamyl alcohol, which was again thoroughly mixed and centrifuged. The resulting 
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aqueous layer was recovered as the purified nucleic acid product. An ethanol precipitation 
was then performed by adding ammonium acetate at a final concentration of 0.75, 1 µl of 
glycogen, and 2.5 times the total sample volume of 100% ethanol. Samples were incubated 
at 20°C and then centrifuged for 20 min at 4°C. The resulting pellet was washed 3 times in 
80% ethanol and resuspended in 10 mM Tris HCl. Samples were further diluted in TE 
buffer (10 mM Tris, 1 mM ethylenediaminetetraacetic acid; EDTA) and mixed with an 
equal amount of Hoechst 33258 dye dissolved in TNE buffer (10 mM Tris, 1 mM EDTA, 
2 M sodium chloride, 2 mM sodium azide). Sample fluorescence intensity was measured a 
POLARstar Omega plate reader (BMG Labtech, Inc., Cary, NC) and compared to calf 
thymus standards. 
 
2.4.3 Genipin-Induced dECM Hydrogel Crosslinking 
Digested dECM at a concentration of 6 mg/ml was crosslinked with genipin using either 
5mM, 7.5 mM, or 10 mM total genipin. As genipin produces a fluorescent crosslink as a 
result of reactions with free amine groups, fluorescence was used as a tool to quantify 
crosslinking completion. dECM-genipin mixtures were pipetted into the wells of a 96-well 
plate and incubated for 24 hours at 37°C. Crosslinking was monitored using a POLARstar 
Omega plate reader (BMG Labtech, Inc., Cary, NC) measuring fluorescence over 24 h 
(λex = 584 nm and λem = 620 nm). Hydrogel precursor solutions were plated into a 96-well 
plate and inserted into the plate reader, which was pre-warmed to 37°C. As genipin 
produces a fluorescent crosslink as a result of reactions with free amine groups, 
fluorescence was used as a tool to quantify crosslinking completion. Fluorescence intensity 
data was collected every hour for the duration of the experiment.  
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A colorimetric ninhydrin assay was performed in order to determine the concentration of 
free amines in genipin-crosslinked hydrogels, thus measuring the extent of the crosslinking 
reactions [59, 70]. Briefly, ninhydrin solution was added to crosslinked hydrogels 
suspended in sodium citrate buffer, as well as standard solutions of known amine 
concentrations. The samples and standards were then placed in a boiling water bath for 
15 min and then allowed to cool for 30 min. Sample absorbances were measured at a 
wavelength of 570 nm using a POLARstar Omega plate reader (BMG Labtech, Inc., Cary, 
NC). In addition, methanol content was assessed over the duration of genipin-induced gel 
crosslinking using a methanol assay kit (BioVision Inc., Milpitas, CA). The assay uses an 
enzymatic mechanism to quantify methanol production through generation of a 
colorimetric signal. Hydrogels were crosslinked with genipin as described previously in 96 
well plates. During the crosslinking reaction, liquid samples were removed from each well 
at specific time points (2.5 h, 8 h, 15 h, and 24 h) to assess the amounts of methanol 
produced as the crosslinking progressed. Samples and pure methanol standards were mixed 
with the methanol assay buffer, developer, enzyme mix, and the methanol probe as per the 
manufacturer’s instructions, incubated at 30°C for 30 min, and absorbance were measured 
at a wavelength of 450 nm using a POLARstar Omega plate reader (BMG Labtech, Inc., 
Cary, NC). 
 
2.4.4 Rheological Properties 
Genipin crosslinked gels were pre-formed using the protocol described above. The 
viscoelastic properties of the hydrogels were analyzed using a rheometer (Physica MCR 
301; Anton Paar, Graz, Austria) with an 8 mm parallel plate geometry and a 1 mm gap 
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between plates. A dynamic frequency sweep was performed (0.25-100 rads s-1) at 2.5% 
strain to determine the storage modulus (G’) and the loss modulus (G’’). All measurements 
were performed at room temperature. 
 
2.4.5 Enzymatic Degradation 
Genipin-crosslinked dECM hydrogels were formed using the previously described 
protocol, except gels were crosslinked in 2 ml microcentrifuge tubes. Type 1 Collagenase 
(Thermo Fisher) was dissolved in Hank’s Buffered Saline solution (HBSS; Thermo Fisher) 
containing 0.9 mM calcium chloride (CaCl2) at a concentration of 150 U/ml. Following an 
initial weight measurement of each fully crosslinked gel, 0.5 mls of collagenase solution 
was added into each gel-containing microcentrifuge tube and the hydrogel weights were 
monitored over a period of thirty days by removing the liquid and weighing the remaining 
gel at each time point.  
 
2.4.6 Cell Viability 
Genipin crosslinked dECM hydrogels were formed as described previously in 96 well 
plates. Hydrogels were then rinsed with PBS three times for 1 h, followed by two 
subsequent 1-h cell culture media washes and an overnight media wash to ensure that 
residual genipin and the low levels of methanol generated during crosslinking were 
removed (Figure 2.2, Reaction 2). Following the rinse steps, gels were sterilized by 
irradiation with ultraviolet (UV) light overnight in a laminar flow hood. Three types of 
cardiac and vascular cells were assessed for viability on the dECM hydrogels: human 
cardiac fibroblasts (CFs, passage 2-3; Cell Applications, San Diego, CA), human neonatal 
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cardiomyocytes (CMs; Sciencell; Carlsbad, CA), and human umbilical vein endothelial 
cells (HUVECs, passage 4; Lonza, Walkersville, MD). Cells were seeded at a density of 
20,000 cells/gel and cultured for 24 h on hydrogel surfaces. A Live/Dead cell viability 
assay (Thermo Fisher) was then used to assess the numbers of live and dead cells on each 
gel. In brief, cells were stained with a combination of calcein-AM, ethidium homodimer-1, 
and 4,6-diamidino-2-phenylindole (DAPI), resulting in green-fluorescent live cells and 
red-fluorescent dead cells, respectively. Cells were imaged using an EVOS FLoid Cell 
Imaging Station (Thermo Fisher), and the number of live and dead cells were quantified. 
 
2.4.7 Human Adipose Stem Cell Differentiation 
Human adipose stem cells (hADSCs; passages 2-3; Lonza) cultured in human adipose-
derived stem cell growth media (Lonza, Walkersville, MD) were seeded onto 7.5 mM 
genipin-crosslinked dECM hydrogels, non-crosslinked dECM, Type I porcine collagen 
gels or TCPS at a density of 7,500 cells per well. Hydrogels were crosslinked as previously 
described in 96-well plates and rinsed to remove residual genipin and methanol as 
described above. Cells were cultured for either 3 days, or 1, 2, or 3 weeks in a humidified 
incubator with 5% CO2 at 37°C, and the culture media was changed every 48 hours. 
Following the specified culture period, RNA was extracted and isolated from the cells 
using TRIzol Reagent (Invitrogen) according to the manufacturer’s protocol. Samples were 
stored at -80°C until reverse transcription was performed. For reverse transcription, the 
Power SYBR® Green Cells-to-CT™ kit (Invitrogen) was used according to manufacturer’s 
protocols. Briefly, for each reaction, 25 µls of 2X SYBR® RT Buffer, 2.5 µls RT Enzyme 
Mix, and 12.5 µls nuclease-free water were added to each well along with 10 µls of the 
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RNA sample. Samples were heated for 60 minutes at 37°C, followed by 5 minutes at 95°C 
for enzyme inactivation using a C1000 Touch Thermal Cycler (Bio-Rad, Hercules, CA), 
and then cooled to 4°C. cDNA samples were stored at -20°C until use. 
 
2.4.8 Quantitative Real-Time PCR (qRT-PCR) 
Relative gene expression was quantified by qRT-PCR using a CFX348 Touch Real-Time 
PCR Detection System (Bio-Rad). Briefly, using the Power SYBR® Green Cells-to-CT kit 
(Invitrogen), a master mix was made for each primer set consisting of the following: 5 µls 
Power SYBR® Green PCR Master Mix, 0.04 µls each of forward and reverse primers 
(Integrated DNA Technologies), 2.96 µls of nuclease-free water, and 2 µls of cDNA for a 
final volume of 10 µls. Samples were run at 95°C for 10 minutes, followed by 40 cycles of 
95°C for 15 seconds and 60°C for 1 minute. Gene expression was normalized to the 
housekeeping gene eukaryotic translation elongation factor 1 alpha 1 (eEF1A1). The 
resulting data was analyzed as fold expression change of our experimental groups relative 
to collagen controls using the -∆∆CT method for non-integrin blocked groups, and for 
integrin blocked groups relative to their non-blocked counterparts. 
 
2.4.9 Functional Blocking Studies 
In order to determine the influence laminin and fibronectin have on the differentiation of 
hADSCs, 7,500 passage 3 hADSCs were incubated in media containing either 10 µg/ml of 
laminin receptor antibody (anti-integrin beta 4; Abcam, Cambridge, MA), 10 µg/ml of 
fibronectin receptor antibody (anti-integrin beta 5; Abcam), or both (10 ug/ml each). Cells 
were then seeded onto genipin-crosslinked dECM hydrogels and cultured for either 3 days, 
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or 1, 2, or 3 weeks. The antibody-containing culture media was changed every 2-3 days. 
Following the specified culture times, RNA was collected using the above-described RNA 
isolation protocol and relative gene expression was quantified as described previously. 
 
2.4.10 Immunohistochemistry Studies 
In order to determine the protein expression of genes analyzed using qPCR, 
immunohistochemistry analysis was conducted for the following markers- NKX2.5 
(Thermo Fisher), cardiac troponin T (cTnI, Thermo Fisher), connexin 43 (Thermo Fisher), 
and sarcomeric alpha sctinin (Abcam). Briefly, hADSCs that were seeded on gels were 
rinsed with PBS, then fixed with 4% PFA for 15 minutes. Following fixation, gels were 
cryoprotected in 10%, 20%, and 20% sucrose/PBS solutions, remaining in each 
concentration until the gel sunk to the bottom of the tube. Gels were then mounted in 
cryomount OCT (VWR), and snap frozen using liquid nitrogen, and stored at -80°C until 
use. Gels were sectioned at 7 µm in a Leica CM3500 cryotome, using a Cryojane® Tape 
transfer system and stored at -20°C until use. Sections to be stained were brought to room 
temperature, permeabilized in 0.2% triton-PBS for 15 minutes, rinsed in PBS, then blocked 
in 5% BSA for 1 hour at room temperature. Following blocking, antibodies listed above 
were incubated on the slide overnight at 4°C. Slides were rinsed in PBS, and secondary 
antibodies, FITC-anti rabbit, or FITC-anti mouse (Abcam, or Thermofisher) were applied 
to the slides for 1 hour at room temperature. Slides were rinsed in PBS 3 times for 5 
minutes each, and counterstained with DAPI to visualize the nuclei. Sections were 
mounted using Pro-Long Diamond Antifade Mountant (Thermo Fisher) and visualized 
using fluorescent microscopy. 
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2.4.11 Statistical Analysis 
The statistical analysis of all data was performed using GraphPad Prism 7 (GraphPad 
Software Inc, La Jolla, CA, USA). Data are presented as mean ± standard deviation. 
Statistical comparison between groups were performed using either students unpaired t-test 
(viability studies) a one-way analysis of variance (ANOVA) with Tukey’s multiple 
comparison test (rheological studies) or a two-way ANOVA with Tukey’s multiple 




2.5.1 Evaluation of Decellularization Efficiency 
To visualize the efficiency of decellularization, the opaque myocardial tissue pieces 
(Figure 2.1B) were evaluated for residual dsDNA content. Residual dsDNA content was 
2.474 +/- 0.211% dsDNA, compared to its non-decellularized tissue counterpart. 
Additionally, the standard of less than 50 ng dsDNA/mg tissue was met, and recorded to be 














Figure 2.1: Decellularization Efficiency. (A) Cadaveric porcine left 
ventricular tissue prior to decellularization. (B) Decellularized porcine left 
ventricular tissue. (C) dsDNA content of decellularized ventricular tissues 
as compared to fresh control tissues. Data represent mean ± SD; n = 6, *p 










2.5.2 Crosslinking Behavior of dECM Hydrogels 
 
  
Genipin crosslinking with free amine residues forms a fluorescent byproduct that emits at 
620 nm, which can be used to track the progress of the crosslinking reaction (Fig. 2.4). 
Control gels without genipin exhibited no fluorescence intensity change (Fig. 2.3A). Peak 
fluorescence intensity across all groups was achieved at ~5 hours after initial mixing with 
genipin and the signal plateaued thereafter. dECM hydrogels+ genipin that had been 
formed from dECM solutions digested for only 24 hours in pepsin peaked at a higher 
fluorescence intensity across all three concentrations of genipin and maintained a higher 
plateau at around ~300 nm (Fig. 2.3B,C,D).  
Fig. 2.2: Protein Composition of dECM. A) 24 hours of pepsin digestion, B) 48 hours of pepsin 
digestion, and C) 72 hours of pepsin digestion. ECM protein mass compositions are different across the 








Thus, these data present evidence that dECM hydrogels crosslinked with solutions made 
from 24 hour of digested dECM hydrogels (p<0.05) crosslinked faster, and may produce 
more fluorescent crosslinks due to the availability of sites for crosslinking. Additionally, 
these data show that full crosslinking is assumed to be complete by ~5 hours, as the 
fluorescent signal plateaued at this point. 
 
 
Figure 2.3: Gelation of Genipin-Crosslinked dECM Hydrogels. Observed by tracking the 
fluorescence intensity of by-products of genipin crosslinking at 37°C (λex = 584 nm, λem = 620 nm). 
(1) dECM + 0 mM genipin, (2) dECM + 5 mM genipin, (3) dECM + 7.5 mM genipin, and (4) 
dECM + 10 mM genipin. Across all groups, gels formed from dECM digested for 1 day in pepsin 
peaked at a faster rate and reached higher fluorescence intensity values overall. Data represent 







2.5.3 Characterization of Material Strength  
To evaluate the strength of the cross-linked dECM hydrogels, storage and loss modulus 
(G’, G”) was recorded. Interestingly, gels that were formed from with both 7.5 and 10 mM 
genipin exhibited a higher storage modulus for gels that were formed from dECM digested 
Figure 2.4: Schematic of Genipin Crosslinking. Depicts crosslinking reaction involving genipin and 
dECM peptide fragments. Reaction 1 involves the nucleophilic attack of genipin by a primary amine, 
leading to the formation of genipin-linked protein fragment that undergoes initial crosslinking as 
indicated by the Phase 1 crosslinking reaction. Reaction 2 is slower and involves the nucleophilic 
substitution of a genipin ester group to form a secondary amide link to available dECM fragments, 
resulting in the release of methanol. Dashed arrows indicate how further reactions of the products from 




for 24 hours vs. 72 hours (7.5 mM: 314.65 +/- 26.11 rads/s vs. 523.95 +/- 58.265; 10 mM: 
627.36 +/- 52.704 rads/s, vs. 356.31+/- 49.29; Fig. 2.5A) (p<0.05). Gels cross-linked with 
5 mM of genipin did not show any differences based on digestion times.  
 
Degradation of the hydrogels by collagenase was evaluated over 30 days. During the first 
five days after initial weights were recorded, linear regression was performed to analyze 
the degradation rate of change.  The rate of degradation of the gels formed from either 24 
or 72 hour digested dECM was different for the 5 mM and 10 mM genipin + dECM 
hydrogel groups (p<0.05). The rate of degradation was slower in gels formed from 24 hour 










2.5.4 Viability of Cardiac Cells 
To determine the biocompatibility of the crosslinked digested ECM, multiple cardiac cell 
type viability was assessed using a live/dead stain, which showed that overall cell viability 
remained high. HUVEC cell viability was 98.38% +/-2.24% across all three genipin 
concentrations and digestion days (Fig. 2.6A). Cardiac fibroblasts showed over 100% live 
cell count across all three genipin concentrations and digestions days, indicative of 
proliferation as well (Fig. 2.6B). Interestingly, cardiomyocytes seeded on gels that were 
formed from dECM that had been digested in pepsin for only 24 hours and crosslinked 
with either 7.5 or 10 mM genipin showed the highest average cell viability, however, only 
a difference was observed in the 5 and 10 mM genipin groups between digestion times 
(Fig. 2.6C). This was attributed to the material composition of the gel; as the digestion 
Figure 2.5: Rheological Properties of Genipin-Crosslinked dECM Hydrogels. (A) Assessed by 
performing frequency sweeps of hydrogels formed using dECM obtained after 1, 2, or 3 days of pepsin 
digestion, and increasing amounts of genipin concentration. At 0.25 rads/s genipin-crosslinked dECM 
hydrogels made shows significant increases in storage modulus with increasing genipin concentration 
for 7.5 mM and 10 mM gels, while genipin-crosslinked dECM hydrogels made from 3 days of pepsin 
digestion showed no significant changes with varying amounts of genipin. Data represent mean ± SD; n 
= 3 per digest day group, *p < 0.05. (B), (C) Collagenase-mediated degradation profiles of dECM 
hydrogels that were made from dECM solutions digested with pepsin for either (B) 1 day, or (C) 3 days, 
and then crosslinked with either 0, 5, 7.5, or 10 mM of Genipin. Gels that were formed from 1 day of 
pepsin digestion degraded more slowly than gels that were formed from 2 days or 3 days of digestion, 
but gels formed with varying amounts of genipin all showed similar degradation profiles. All groups 





time was only 24 hours in pepsin, the protein fragments should be larger and therefore may 







2.5.5 Differentiation of ADSCs Towards Cardiac Phenotype  
The differentiation of ADSCs towards a cardiomyocyte lineage with and without blocking 
of β4 and β5 integrins by quantitative PCR (qPCR) showed certain cardiac specific gene 
expression upregulated. qPCR showed significant upregulation of cTnI, and sarcomeric 
Figure 2.6: Cell Viability in Genipin-Crosslinked dECM Hydrogels. (A, D) HUVECs, (B, E) cardiac 
fibroblasts, and (C, F) cardiomyocytes on genipin-crosslinked dECM hydrogels. A) HUVECs seeded 
on 24 hour digested dECM showed higher viability compared to 72 hour digested dECM. B) No 
statistically significant differences were observed between hydrogels made from different pepsin 
digestion days for cardiac fibroblasts. C) Cardiomyocyte viability was significantly higher for cells 
cultured on 7.5 and 10 mM genipin-crosslinked dECM hydrogels as compared to 0 mM and 5 mM 
genipin-crosslinked dECM hydrogels. Cardiomyocytes seeded on hydrogels digested in pepsin for 24 
hours showed higher cell viability than 72 hour digested counterparts for the 5 mM and 10 mM 




alpha actinin in the β4 and β5 integrin blocked groups compared to all other groups 
(p<0.001) (Fig. 2.7). Additionally, expression of both MLC2 atrial and MLC2 ventricular 
isoforms of myosin light chain, was significantly up-regulated by 3 weeks compared with 
the genipin + dECM groups (p<0.001) (Figure 2.8, 2.10). Cells seeded only on genipin + 
dECM groups showed no expression of MLC2 until 2 weeks in culture, with a statistically 
significant difference seen 3 weeks post cell seeding (p<0.05) (Fig. 2.10). Expression of 
cTnI was not detected in qPCR until 2 weeks post cell seeding, and increased gradually 
over, with no differenes between groups (Fig 2.7. B, Fig 2.10). Sarcomeric alpha actinin 




Figure 2.7: Expression of Cardiac Genes in Genipin-Crosslinked dECM Hydrogels. 7.5 mM dECM 
hydrogels digested for 24 or 72 hours, and either B4, B5, or B4+5 integrins blocked. Connexin 43 
expression on 24 hour pepsin digested dECM +7.5 mM Genipin gels 1 week post cell seeding D) and 3 
weeks post cell seeding E). TnnT2 expression on 24 hour digested dECM 1 week post cell seeding F) and 
3 weeks post cell seeding G). Sarcomeric Alpha Actinin staining on 24 hour digested dECM 1 week post 
cell seeding H), and 3 weeks post cell seeding I). Data represents mean +/- SD. N=3 for each time-point 
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seeded on 72 hour digested dECM + genipin, after 2 weeks were significantly higher than 
all the other groups (p <0.05). 
 
2.5.6 Activation of β1 integrin on hADSCs 
To determine whether the increase in cardiac gene expression was due to the activation of 
the β1 integrin by the β4 and β5 integrins, a β1 integrin blocking antibody was incubated 
with hADSCs prior to seeding on genipin + dECM hydrogel surfaces. After 1 week in 
culture, activated β1 integrin was measured on cell surfaces (HUTS-4). The amount of 
positive HUTS-4 staining on β4+β5 blocked hADSCs that had been seeded on hydrogels 
digested for only 24 hours (44.02% +/-3.39) was significantly higher than cells seeded on 
gels made from dECM digested for longer (27.37% +/-4.92, p<0.05) (Fig. 2.11 D, H). To 
see whether blocking β1 integrin would eliminate the activation of the integrin, or if the β4 
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Supplementary Fig. 2.9: Expression of certain cardiac genes on 7.5 mM dECM hydrogels digested for 24 or 72 hours, 
and either B4, B5, or B4+5 integrins blocked. A) MLC2 atrial isoform expression showed significant up-regulation in 
gene expression compared to unblocked controls 3 weeks post cell seeding. B) MLC2 ventricular isoform was not 
detected until 2 weeks post cell seeding, and was significantly higher than its unblocked counter part. Data represents 
mean +/- SD. N=3 for each time-point and each group. 
MLC2: Myosin Light Chain
A)
Figure 2.8: Expression of MLC2A and MLC2V. 7.5 mM dECM hydrogels digested for 24 
or 72 hours, and either B4, B5, or B4+5 integrins blocked. A) MLC2 atrial isoform 
expression showed significant up-regulation in gene expression compared to unblocked 
controls 3 weeks post cell seeding. B) MLC2 ventricular isoform was not detected until 2 
weeks post cell seeding, and was significantly higher than its unblocked counter part. Data 







combinations (β1+β4, β1+β5, and β1, β4, and β5). Interestingly, across all three groups β1  
activation was detected (Fig. 2.11 B, C, E, F). This suggests the intracellular connectivity 
between the β integrin subunits, and further implicates their role in cardiac differentiation.  
 
2.6. Discussion 
As ADSCs are an emerging and promising potential source for cardiovascular disease 
treatment, more studies into the differentiation of ADSCs into cardiomyocyte like cells 
have been conducted [213]. Previous studies have shown the capacity of ADSCs to  
Figure 2.9: Expression of Cardiac Genes on Control dECM Hydrogels. 7.5 mM dECM hydrogels digested 
for 24 or 72 hours no integrins blocked. A) MLC2 ventricular isoform expression showed significant up-
regulation in gene expression on 24 hour digested dECM compared to controls 72 hour digested dECM 3 
weeks post cell seeding. B) MLC2 atrial isoform was not statistically different between digestion groups. C) 
cTnI expression was not detected until 2 weeks post cell seeding, and was significantly higher after 2 weeks 
in the 24 hour digested group. D) MYHC6 was not detected in 72 hour digested dECM E) MYHC7 
expression was not detected in 72 hour digested dECM groups throughout seeding.  
D) E)
A) B)
Supplementary Fig. 2: Expression of certain cardiac genes on 7.5 mM 
dECM hydrogels dige ted for 24 or 72 hours no integrins blocked. A) 
MLC2 ventricular isoform expression showed significant up-regulation in 
gene expression on 24 hour digested dECM compared to controls 72 hour 
digested dECM 3 weeks post cell seeding. B) MLC2 atrial isoform was 
not statistically different between digestion groups. C) cTnI expression 
was not detected until 2 weeks post cell seeding, and was significantly 
higher after 2 weeks in the 24 hour digested group. D) MYHC6 was not 
detected in 72 hour digested dECM E) MYHC7 expression was not 
detected in 72 hour digested dECM groups throughout seeding. 
Data represents mean +/- SD. N=3 for each time-point and each group. 
MLC2: Myosin Light Chain, cTnI: Cardiac Troponin T, MYHC6: Myosin 
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differentiate into different cardiac lineages such as cardiomyocyte, fibroblast, endothelial, 
and smooth muscle [213, 214]. Indeed, studies have seen varying amounts of effective 
differentiation efficiency, with conflicting results on cardiomyocyte integrity. While there 
are differing opinions on the efficacy of the differentiation of the cells, there nevertheless 
remains the clinical data showing that ADSCs are anti-inflammatory, pro-angiogenic, and 
may be beneficial when injected post- MI.  
 
Recently, new technologies have been developed that may be used to help encourage the 
differentiation of ADSCs towards cardiomyocytes, such as the processing of decellularized 
tissues into hydrogels. These gels have been shown to retain the intrinsic cues necessary to 
differentiate mesenchymal cells towards a cardiac lineage [215]. The environment 
provided by the dECM hydrogel enables cells to be exposed to similar conditions as in 
vivo; as the majority of the ECM components are retained through processing [75]. When 
coupled with a crosslinker with low cytotoxicity, dECM gels can also provide cells with an 
environment that is more mechanically similar to in vivo conditions as well. In addition to 
the capability to differentiate stem cells towards tissue specific lineages, these gels may 
also be used as a potential delivery vehicle for bioactive factors, which could then be used 
to further drive differentiation [216]. As currently there are cardiac hydrogels, VentriGel 
(Ventrix, San Diego CA) in Phase I clinical trials, further investigation into how the 
processing of the tissue affects the final product, and subsequently cell behavior is 
necessitated. Further, because of the similar in vivo environment that the dECM hydrogels 
possess, elucidating how to differentiate stem cells more efficiently utilizing this 
technology is valuable.  In this study, we aimed to expand upon previous studies 
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characterization of cardiac dECM hydrogels and investigate how differential processing of 
the dECM affects the final material characteristics and downstream applications such as 
differentiation of ADSCs into cardiomyocyte like cells. We further elaborated on the 
differential composition of the resulting hydrogels by utilizing in vivo integrin signaling 
pathways known to be important in the differentiation of cells early in cardiac 
development.  
 
We found that the length of time that the dECM is digested not only affects the material 
properties, but also cell behavior. As the length of digestion is increased, and proteins are 
broken down into smaller fragments, the mechanical strength of the material should be 
altered due to the presence of more available crosslinking sites. However, our results 
indicated a different finding; after just 24 hours of digestion the highest G’ was observed in 
the 10 mM genipin group, compared to 72 hours of digestion (Figure 2.5A). This was 
attributed to the size of the proteins that were available and the accessibility of the genipin 
to the protein. In the 5 mM genipin group, there were no differences noted between dECM 
digestion times. This lack of difference was hypothesized to be due to the concentration of 
the genipin relative to the available sites for crosslinking, which can affect the final 
material elasticity. The stiffness of a material has been shown previously to heavily 
influence stem cell differentiation, such as mesenchymal stem cells [217, 218]. Stiffness 
alone can help determine whether a cell will differentiate towards an osteogenic or a 
neurogenic lineage. Although the observed differences in G’ were minimal, we can 
attribute some of the differences seen in our cell differentiation to the different G’ 
measurements of the dECM + genipin hydrogels.  
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In addition to mechanical stiffness as a driving force of differentiation, protein composition 
of the extracellular matrix can influence cell signaling and consequently differentiation. 
Indeed certain proteins such as laminin and fibronectin have been implicated for their role 
in cardiac differentiation, with laminin in particular being important [219]. In proteomic 
analysis of the different digestion times, fibronectin, an important component of the ECM 
known for its role in cardiovascular development, decreased by approximately 40% when 
the digestion time was extended to 72 hours (compared to 24 hours; Fig 2.2). Although the 
fibronectin remained a small percentage of the overall protein composition of the dECM at 
both digestion times, even the slightest change in material composition can influence the 
behavior of cells and influence differentiation of stem cells. Another protein, Collagen V 
has been recently implicated in its role in cardiac differentiation. Indeed, the detected 
Collagen V decreased from 10.92% in 24 hour digested dECM hydrogels, to 7.27% after 
72 hours of digestion. This disparity in Collagen V may help explain the differences noted 
in cardiac gene expression in our control hydrogels, which has shown to have a pro-
cardiogenic effect (Figure 2.9)[220]. Because of the role of proteins in cell differentiation, 
we wanted to consider whether this difference in material composition could actually be 
the cause of the different cell behavior seen in the qPCR data, and did so by blocking the 
cell’s ability to recognize certain proteins via integrins.  
 
Based on previous studies completed, we believed that by blocking the β4 and β5 integrins 
we would be aberrantly affecting the cell differentiation. Instead, we found that by 
blocking the activity of β4 and β5 integrins, we increased the expression of certain 
cardiomyocytes specific genes (Fig. 2.7). This was hypothesized to be from a possible 
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increase in activation β1 integrin, and therefore it activity, which is critical to 
cardiomyocyte development. We found that by inducing increased β1 activity, we induced 
increased expression of both atrial and ventricular isoforms of myosin light and heavy 
chain proteins, and cardiac troponin I.  For other genes, such as gap junction protein 
connexin 43, only slight increases in expression were seen when compared to cells whose 
integrins were unblocked.  This was attributed to previous work that had found that β1 
integrin function negatively regulates connexin expression, and if β1 integrin activity is 
supposedly increased in our model, then it follows that expression would not be increased 
(Fig 2.7)[209, 221].  Interestingly, early genes known to be critical to cardiac development 
such as GATA4 and NKX2.5 were expressed either very low, or were not detectable in 
qPCR analysis. NKX2.5 however, was detected via immunohistochemistry. Because low 
to no early cardiac gene expression was detected, we believe this gave evidence of the 
possible role of the integrins in the expression of more mature cardiomyocyte markers. 
 
Previous studies have shown the crosstalk between integrin’s and the significance that 
crosstalk can have on cell migration, adhesion and behavior [208]. The signaling that 
occurs via integrin’s typically is induced by ligand binding, i.e. ECM, and is termed 
“outside in” signaling [208]. However, integrin cytoplasmic domains may also be altered 
by active non-integrin receptors, known as “inside-out” signaling, which can cause 
integrin’s to be switched from an inactive state to a high affinity state [208]. In a study 
performed by Bernstein et al, the blocking of αVβ5 integrin indeed increased β1 activity, 







found that when the levels of β5 integrin increased, β1 integrin binding to 
collagen/fibronectin matrix increased, while β1 integrin activity decreased [212]. This not 
only suggests the interconnected relationship that the β integrin’s possess, but also 
provides preliminary evidence that intracellular signals help to dictate other integrin 
confirmations. In our study, we found that by blocking β4 + β5 integrin, and with β1 
integrin blocked, active β1 integrin was still seen via immunohistochemistry (HUTS 4; 
Fig. 2.11). Interestingly, hADSCs that were seeded on gels made from 24 hour digested 















Figure 2.10: Expression of Connexin 43 on Cell Surfaces. Gap junction protein (green) and nuclei 
(blue) on the surface of hADSCs seeded onto dECM hydrogels +genipin that had been digested for 72 
hours only. Distinct areas of connexin expression are more obvious over time within these images as 
seen as distinct brighter green fluorescence.  
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dECM appeared to show a higher overall amount of active β1 integrin compared to the 72 



















Figure 2.11: Activated B1 Integrin. Expression in hADSCs seeded on 24 hour digested dECM 
hydrogels + 7.5 mM genipin (HUTS4, Green, DAPI, Blue)  (A, B, C, D), or 72 hour digested dECM 
hydrogels + genipin (E, F, G, H), 1 week post cell seeding. A) 7.5 mM Genipin + 24 hour digested 
dECM, B) B4 integrin blocked, C) B5 integrin blocked, D) B4+5 integrin blocked. E) 7.5 mM 






In this work, we demonstrated that the digestion time of decellularized extracellular matrix 
hydrogels affects cell and final hydrogel behavior. Additionally, we researched how the 
digestion time and resulting protein composition influences adipose derived stem cell 
differentiation towards a cardiomyocyte lineage. Adipose derived stem cells expressed 
certain cardiac specific genes 2 and 3 weeks post cell seeding, with cells seeded on 24 hour 
digested dECM exhibiting significantly higher expression than those seeded on 72 hour 
digested dECM of cardiomyocyte-specific markers. Because protein composition affects 
cell differentiation during development, it would be advantageous to utilize a dECM 
hydrogel and customize it through digestion to induce differentiation to a specific cell 
lineage [222, 223]. Here, we showed that not only the protein composition, but also the 
integrin signaling affects the ability of adipose derived stem cells to trans-differentiate. By 
blocking both the β4 + β5 integrins, we hypothesized that the increase in cardiac marker 
expression was due to the increased activation of the β1 integrin, and showed this through 
immunohistochemistry staining. This work suggests that integrin signaling and ECM 
composition in combination play a large role in the trans-differentiation of stem cells 
towards a cardiomyocyte lineage, and that further studies into the roles of these integrins in 







3 OPTIMIZATION OF SUSTAINED SEQUENTIAL ANGIOGENIC GROWTH 
FACTOR DELIVERY FROM COLLAGEN HYDROGELS 
 
3.1 Overview 
In tissue engineering, many challenges exist on the path to creating scaffolds that may be 
used as an in vivo tissue replacement or graft. Few however, are as large as the 
vascularization of said scaffolds for use in regenerative medicine. Scaffolds must be able to 
support metabolically active tissues, or have the ability to support vascular growth into the 
scaffolds from host tissues. Recently decellularized scaffolds have been utilized in tissue 
engineering as they retain native extracellular matrix and vascular conduits are retained 
until the 2/3 order of branching. Microvasculature, however, is degraded in this process 
and therefore still cannot long term support metabolically active tissues. In this study, I 
have developed a collagenous-based angiogenic growth factor delivery system for use in 
decellularized scaffolds. By combining potent angiogenic growth factors such as vascular 
endothelial growth factor A (VEGF-A), Platelet derived growth factor ββ (PDGF- ββ) and 
Angiopoietin 1 into a collagen scaffold release of said molecules is controlled by charge 
and molecular weight. I show that the use of these growth factors increases cell migration 
and positively influences angiogenesis machinery such as the endothelial cell lumen 
formation complex. Then, by using a 3D dECM hydrogel as in vitro model of a 
decellularized scaffold environment, I show evidence that these growth factors would 
positively encourage endothelial cell migration and subsequent invasion into said 
scaffolds. This research lays the groundwork for future studies in utilizing the collagenous 




In tissue engineering, vascularization of biomaterials continues to be one of the leading 
challenges. Often, the biomaterials used are synthetic or natural in origin, and are not 
inherently vascularized. When applied to an in vivo environment these materials are 
expected to engraft with local tissue and be invaded by vascular cells. However, because of 
the slow in vivo angiogenic growth rate, different methodologies to increase the vascular 
growth rate into/out of a scaffold by modulating the scaffold to be a more angiogenic 
conductive environment have been explored. Recently, decellularization has emerged as a 
new technique to create scaffolds for tissue engineering that retains the native vasculature 
conduits. In 2008, our lab pioneered the decellularization of whole heart scaffolds, and 
showed that when the cellular contents were removed, the vascular conduits still remained 
up to the 2 and 3rd order of branching [23, 62]. Because of the retention of existing 
vasculature endothelial cells can be utilized to then repopulate these conduits- potentially 
solving the need for methods to increase the vascularization of tissue-engineered 
specimens. However, the microvasculature within these scaffolds is degraded by 
decellularization, which renders them not able to support a metabolically active tissue 
long-term [224].  
Different ways to approach the low level of microvasculature regrowth within 
decellularized scaffolds shave been explored including chemical modification to the 
scaffold, utilizing both stem and progenitor cells, and bioactive molecule delivery [225]. 
Typically, re-endothelialization of an acellular scaffold is accomplished via perfusion and 
the scaffolds are perfused with stem cells, endothelial progenitor cells, or adult endothelial 
cells [226]. While some groups have seen success using a combination of both stem that 
 
 80 
can differentiate into supporting cell types and adult endothelial cells, the rate of 
microvasculature growth is still insufficient. Chemical modifications to the scaffold itself 
have included the use of chemicals such as heparin that has been immobilized to a scaffold, 
or heparin gel coating on the scaffold surface to help with endothelial cell adhesion [227, 
228]. In decellularized scaffolds this chemical modification has been coupled with 
bioactive molecules known for their role in angiogenesis, such as VEGF, to help increase 
the amount of vasculature that is formed within a scaffold, and also encourage vascular cell 
in growth to the scaffold.  
 
Angiogenesis is a multifaceted process in which new vascular vessels form from pre-
existing vessels [229, 230]. This process begins with the proliferation of endothelial cells 






























such as CDC42, 
and Rac1
Figure 3.1 Angiogenesis Steps; A) Early- influence of VEGF on the proliferation of ECs, and 
work of MT1-MMP and α2β1 to help control the migration of the cells. B) Tube formation and 
sprouting of ECs; PDGF aides in chemotaxis and tube formation. C) Late-lumen stabilization 




of primitive tubules by these cells, connection of adjacent tubes, and finally lumen 
formation and stabilization of the tubes, leading to a mature microvessel (Figure 3.1). 
 
Throughout this process, specific signaling molecules are expressed at different time points 
as the new vessel grows. VEGF-A is an initiator of angiogenesis and causes the initial 
proliferation of ECs. Following the early stages of angiogenesis, a cascade of different 
signaling molecules is expressed, including PDGF. PDGF acts to stimulate EC 
proliferation, migration, tube formation, and also stimulate the secretion of VEGF from 
ECs [11]. In later stages of angiogenesis, Ang-1 promotes survival of ECs and vessel 
stabilization [11].  
 
One of the most critical steps in angiogenesis is the initiation of lumen formation by ECs, 
which is facilitated by a variety of cellular components that function in a coordinated 















collagenase critical in the formation of EC lumen formation [231-233]. Additionally, MT1-
MMP is necessary to amplify signals of various angiogenic growth factors, such as VEGF 
by causing an increase in receptor expression and cell surface localization [132, 231, 233, 
234].  
 
MT1-MMP works in conjunction with the α2β1 integrin to initiate a signaling cascade 
within endothelial cells [232, 235-237]. MT1-MMP also activates the rho-GTPase Cdc42 
[235, 237, 238]. This GTP-ase acts as a downstream effector of MT1-MMP, and its proper 
activation and expression is crucial to the formation of endothelial cell lumens [235-238]. 
The activation of Cdc42 leads to the activation of the Src, B-Raf, C-Raf, and Erk1/2 
causing the rearrangement of the actin cytoskeleton and affecting cell polarity machinery, 
which is important for cell migration [235, 237-239]. Confirmation of the activation and 
expression of these cellular components will confirm that the system I have designed is 
recapitulating the signaling events within angiogenesis, and ensuring the formation of a 
higher density of vasculature. The successful revascularization of decellularized organs 
must facilitate the onset of the MT1-MMP/ Cdc42 signaling cascade to recapitulate 
microvasculature lost during the decellularization process. 
 
Here, I created a system to increase vascularization within tissue-engineered specimens by 
taking cues from nature and utilizing angiogenic growth factors encapsulated within 
collagen scaffolds as a GF delivery vehicle that may be eventually used one day within 
tissue engineered specimens. Three GFs (VEGF-A, PDGF, and Ang1) will be encapsulated 
 
 83 
within collagen, and have been chosen based on their role in angiogenesis at various stages 
of vessel formation and maturation (Figure 3.1). The GFs that have been chosen include 
vascular endothelial growth factor-A (VEGF-A), which induces EC proliferation and 
maturation [240, 241]. Platelet derived growth factor (PDGF) a GF that has been shown to 
enhance viability and migration [242], and Angiopoietin-1 (Ang-1), which contributes to 
blood vessel maturation and stabilization [243], encouraging the final maturation of blood 
vessels. The encapsulation of these GFs within collagen will allow for their controlled 
release, which should promote EC organization into complete monolayers with appropriate 
junction formation. The system is designed to release GFs over a period of time, to allow 
for sufficient time for EC proliferation and formation of microvascular structures. The 
release of GFs will be studied using degradation based kinetics, by utilizing collagenase at 
levels similar to in vivo, and characterized to collect baseline data on the influence of GF 
release on 3D cell cultures. Additonally, I will measure how the addition of the three GFS 
affect the EC lumen formation complex, as it is critical for proper microvascular formation 
ensuring its proper function is crucial.  
 
3.3 Specific Aims 
Specific Aim 2: Create a GF encapsulated collagen delivery system that will deliver 
vascular GFs in a temporally controlled manner 
Specific Aim 2.1: Model release rate of VEGF, PDGF and ANG1 encapsulated within 
collagen hydrogels. I hypothesize that the release of all three GFs will be occur based on 
size, and will occur in the following order; first VEGF, then Ang1/PDGF at the same time.   
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Specific Aim 2.2: Characterize the effect the GFs have on endothelial cells. I hypothesize 
that cells seeded on top of gels that had GFs encapsulated within them will form tubes at a 
higher rate and invade into the collagen gel deeper than control gels without GFs.  
Specific Aim 2.3: Elucidate the effect that the GFs have on certain endothelial cell lumen 
formation complex machinery. I hypothesize that the presence of the GFs will increase the 
amount of Mt1-mmp active in ECs, and activate down stream effectors of the EC lumen 
formation complex such as CDC42 and Rac1.  
Overall Goal for Specific Aim 2: Create a GF encapsulated collagen delivery system that 
will deliver vascular GFs in a temporally controlled manner to be one day used in tissue-
engineered specimens.  
 
Specific Aim 3: Characterization of endothelial cell behavior to growth factor release in a 
simulated in vivo environment  
Specific Aim 3.1: Characterize the ability of endothelial cells encapsulated within collagen 
gels with or without the presence of GFs, layered on top of dECM hydrogels. I hypothesize 
that cells encapsulated within collagen gels with GFs will invade deeper into dECM 
hydrogels than their control counterparts.  
Specific Aim 3.2: Characterize the ability of ECs seeded on top of collagen gels with or 
without GFs to migrate through the collagen and dECM hydrogel. I hypothesize that the 
ability to migrate through the collagen gel will be significantly increased in gels with 
encapsulated GFs, but that they will still not migrate through the dECM hydrogel.  
Overall Goal for Specific Aim 3: To recapitulate in vivo conditions, a sandwich assay 
using collagen gels with or without GFs will be layered on top of dECM hydrogels, and 
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ECs will be seeded on top of the collagen gels, or encapsulated within the collagen gels. 
This will be used to help characterize the dECM vascularization potential in response to 
sequential growth factor release. 
 
3.4 Materials and Methods 
3.4.1 Collagen Film Synthesis and Characterization  
Type I porcine collagen (Advanced BioMatrix, Inc.) was used as the system for sustained 
GF delivery. Collagen solutions were made per the manufacturer’s instructions. Briefly, 
0.5 mls of 10X M199 Media (With Hanks salts; Thermo Fisher) was added to 4 mls of 
collagen solution. The solution pH was then adjusted to 7.2 - 7.6 through the addition of 
0.1M NaOH, as needed. Sterile water (0.5 ml) was then added to this base solution, which 
is maintained at 2-10°C, until use. In the control gels, sterile water was added, and in the 
GF gels, growth factors were added as listed in the table below (Table 3.1). 150 ul of gel 









Growth Factor VEGF-A PDGF-BB Ang1 
Molecular Weight (kDA) 38.2 28.5 70 
Effective dose 50 (ng/ml) 3.1-4.6 3-5 10-40 
Concentration (ng/ml) 3.3 3.3 3.3 




3.4.2 Collagen Degradation  
To characterize the release profile of the GFs from the collagen gels, rate of collagen 
degradation was recorded in gels made using the above protocol, with 40,000 p3-5 
HUVECs (LONZA, Walkersville, Md). Media was changed and collected and stored at -
80°C once a day. Collected media was analyzed for hydroxyproline content (Biovision). 
Hydroxyproline can be used to measure the amount of collagen in a given sample, as the 
hydroxyproline amino acid is unique to collagen. This was used in order to measure the 
rate at which the cells were degrading the collagen, so then an equivalent amount of Type 
1 Collagenase could then be used as an in vitro model of release.  
 
3.4.2.1 Hydroxyproline Assay Procedure 
Assay was performed following manufacturers instructions. Briefly, 100 µls of collected 
media was hydrolyzed in 100 µls of 12 N HCl at 120°C for 3 hours. Samples were then 
allowed to cool, and 10 µls of the homogenate was added into a 96 well plate. A standard 
curve was created using the provided hydroxyproline standard in media and brought to a 
concentration of 0.1 mg/ml. Subsequently 0, 2, 4, 6, 8,and 10 µls of the 0.1 mg/ml 
hydroxyproline stock was added into different wells to create standards of 0.2-2 µg/well 
standards. Both standard and samples were then evaporated to dryness under a vacuum. 
For the reaction, 100 µls of Chloramine T reagent was added into each sample well and 
incubated at room temperature for 5 minutes. 100 µls of DMAB reagent to each well and 
incubated for 90 minutes at 60°C. Immediately afterwards, absorbance was measured at 




3.4.3 Collagenase Concentration Optimization  
The results from the above mentioned hydroxyproline assay were then compared to the 
hydroxyproline release from gels that were exposed to different concentrations of Type 1 
collagenase (Gibco; Figure 3.3). Briefly, Type 1 Collagenase (Gibco) was added onto the 
collagen gels containing the above-mentioned GFs, in order to mimic the effect of cell 
based collagen degradation. Collagenase was added on to the gels at vary times after the 
set “zero” timepoint, to mimic the amount of time it would take for cells to adhere and 
begin to degrade the matrix. Based on the collected data, a 2-hour delay of the addition of 
collagenase was sufficient to mimic the time to adherence of the HUVECs.  
 
3.4.4 Growth Factor Release Quantification 
Samples from gels that had GFs encapsulated within them, after the addition of 0.05 
units/ml of collagenase as determined above, were collected at set time intervals over 22 
days and storing them at -20°C throughout the time course of release. An enzyme-linked 
immunosorbent assay (ELISA) was then performed to quantify the activity of proteins 
released from collagen films. Each GF was individually run on different ELISA plates.  
 
3.4.4.1 ELISA Procedure  
Briefly, each primary antibody (VEGFA- Thermo Fisher, PDGF-BB- R&D Biosystems, 
ANG1- R&D Biosystems) was added onto Nunc MaxisorpÒ 96 well plates (Thermo 
Fisher) at a concentration of 1.25 µg/ml. Primary antibodies were added onto the plates 
using a coating buffer consisting of 1.5 g Na2CO3 2.93 g NaHCO3 into 1 L of distilled 
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water, at a pH of 9.6, overnight at 4°C. The coated plate wells were then emptied, and 
gently patted dry on an absorbent towel. Wells were washed 3 times, repeating the drying 
on an absorbent towel procedure, using a wash buffer consisting of 1xPBS and 0.05% 
Tween 20 (Sigma Aldrich). Next, 150 µl of a blocking solution (PBS with 1% Bovine 
Serum Albumin) was added onto the plate for an hour at 37°C. Well plates were washed 4 
times. 100 µl of the previously collected samples were added into the well plates. 
Standards were created for each respective GF, at concentrations of 1.5, 1.0, 0.75, 0.375, 
0.1875, 0.09375, and 0 ng/ml, in the media that was used for the initial release experiments 
above (Endothelial Growth Media- Lonza). Plates were incubated for 90 minutes at 37°C. 
Well plates were washed 3 times and patted dry. Biotin-conjugated detection antibodies for 
each respective GF (VEGFA- Thermo Fisher Scientific, PDGFBB- R&D Biosystems, 
ANG1- R&D Biosystems) were dilute to a concentration of 0.025 µl per antibody, in the 
above-mentioned wash buffer. 100 µl of each respective solution was added onto their 
corresponding wells, and plates were then incubated for one hour at 37°C. Well plates 
were washed 3 times and patted dry. HRP Conjugated Streptavidin Antibody (Thermo 
Fisher Scientific) was diluted in the wash buffer to a final concentration of 0.05 µg/ml, and 
100 µl of the solution was added into each well, and incubated for one hour at 37°C. Well 
plates were washed 3 times and patted dry. 100 µl of TMB substrate solution (Thermo 
Fisher Scientific) was added to each well, and incubated at room temperature in the dark 
for 30 minutes. After 30 minutes, 50 µl of stop solution (Thermo Fisher Scientific) was 
added onto the wells. Plates were gently tapped to ensure thorough mixing of the stop 
solution and TMB substrate solution. Plates were measured in a plate reader at 570 nM on 




3.4.5 HUVEC Cell Behavior Characterization 
P3-5 HUVECs were serum starved (0.5%) for 4 hours prior to seeding on collagen gels 
with or without GFs encapsulated within them. Cells were seeded at 40,000 cells per cm2 
dependent on the culture dish used. After 3, 7, 14, and 21 days post cell seeding gels were 
collected and fixed with 4% Paraformaldehyde for 15 minutes. Samples were either stored 
overnight at 37°C or immediately stained. Cells were washed 3x for 5 minutes in 1X PBS 
after fixation, and subsequently permeabilized for 15 minutes with 0.1% Triton in 1X PBS. 
Cells were then stained with Fluoresein Phalloidin for 25 minutes, washed, and then DAPI 
for 10 minutes and one final wash step. Gels were inverted onto a microscope slide and 
images on a Zeiss Meta Confocal microscope. Z stacks were taken to allow for 
quantification of invasion to the scaffold.  
 
3.4.6 Cdc42/ Rac1 Activation Assay 
3.4.6.1 Cell Lysate Collection 
P3-5 HUVECs were serum starved (0.5%) for 4 hours prior to seeding on collagen gels 
with or without GFs encapsulated within them. Cells were seeded at 40,000 cells per cm2 
dependent on the culture dish used. After 1, 3, 5, 7, 9, 11, and 14 days samples were 
collected per manufacturers instructions. Both CDC42 and RAC1 assays were conducted 
using a G-LISA® Activation Assay Biochem Kit- Absorbance based (Cytoskeleton, Inc. 
Denver, CO). Briefly, gels are removed from the wells and rinsed quickly in ice-cold 
1XPBS. Gels are then blotted, and put into a microcentrifuge tube containing 400 µl of ice-
cold lysis buffer and protease inhibitors provided by the kit. The gels were then sheared 
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through 18 gauge needles, and then quickly spun at 14,000 RPM at 4°C. Samples were 
then snap frozen in liquid nitrogen and stored in -80°C until the rest of the assay was 
performed.  
 
3.4.6.2 G-LISA® Assay 
On the day of the assay, snap frozen lysates were thawed in a room temperature bath. 
Provided microplates were dissolved in 100 µl of ice-cold water, and then turned over and 
flicked to remove the solution followed by patting on paper towels. The plate was then 
returned to ice, and 50 µl of sample cell lysate was added into wells. Blanks and positive 
controls provided by the kits were added as well. The plate was then shaken on an orbital 
shaker at 400 rpm for 15 minutes at 4°C. Next, plate was washed with 200 µl of provided 
wash buffer and removed, and patted on a paper towel. 200 µl of antigen presenting buffer 
(provided) was then added into the plates for 2 minutes. Antigen presenting buffer was 
then removed, and wells were washed three times with 200 µl of wash buffer and removed, 
then patted dry on a paper towel. Anti-CDC42 primary antibody (diluted in antigen 
presentation buffer) was then added onto each well and incubated on a shaker plate at 400 
rpm for 30 minutes at room temperature. After 30 minutes, antibody was washed 3 times 
with 200 µl wash buffer and removed, and patted dry on a paper towel. Provided secondary 
antibody was diluted in antibody dilution buffer and 50 µl was added to each well and 
incubated on a shaker plate at 400 rpm for 30 minutes at room temperature. After 30 
minutes, secondary antibody was washed 3 times with 200 µl wash buffer and removed, 
and patted dry on a paper towel. 70µl of the provided horseradish peroxidase (HRP) 
reagent was then added into each well and plates were incubated at 37°C for 15 minutes. 
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140 µl of the provided stop solution was added to each well, and immediately measured at 
490 nm using a POLARstar Omega Plate reader (BMG LABtech). CDC42 and RAC1 
assays were completed the same way as mentioned above, but using their respective 
antibody pairs.  
 
3.4.7 MMP14 Activation Assay  
3.4.7.1 Cell Lysate Collection 
Activity of MMP14 was measured using a SensoLyte® 520 MMP14 Assay kit 
(fluorimetric; AnaSPEC Fremont, CA).  P3-5 HUVECs were serum starved (0.5%) for 4 
hours prior to seeding on collagen gels with or without GFs encapsulated within them. 
Cells were seeded at 40,000 cells per cm2 dependent on the culture dish used. After 1, 3, 5, 
7, 9, 11, and 14 days samples were collected per manufacturers instructions. Briefly, cells 
were washed with PBS. Assay buffer (provided) with 0.1% Triton-X 100 was added to the 
cells and incubated at 4°C for 15 minutes. Sample was then collected in a microcentrifuge 
tube, and incubated at 4°C for 10 minutes. Samples were then centrifuge for 15 minute at 
2000 g at 4°C. Supernatant was collected at stored at -80°C until assay was performed.  
 
3.4.7.2 MMP14 Activation Assay 
Provided APMA is activated prior to initiation of experiment for 2 hours at 37°C. Samples 
were thawed and incubated with provided APMA (previously activated at a concentration 
of 1 mM for 3 hours at 37°C. 50 µl of samples were added into wells of a 96 well plate, 
along with positive control provided with kit, and substrate control (just assay buffer). 50 
µl of MMP14 substrate solution (provided with kit) was then added into all wells, and the 
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plate was shaken for 30 seconds, and incubated for 60 minutes in the dark at 37°C, then 50 
µl of provided stop solution was added to the wells, mixed, and fluorescence intensity was 
measured at 520 nm on a POLARstar Omega Plate reader (BMG LABtech) .  
 
3.4.8 Sandwich Assay  
Sandwich assays were completed forming dECM hydrogels using the following protocol.  
dECM was created from porcine left ventricles using a previously established protocol. 
Digested dECM at a concentration of 6 mg/ml was crosslinked with genipin using either 
5mM, 7.5 mM, or 10 mM total genipin solution content. dECM-genipin mixtures were 
pipetted into the wells of a 96-well plate and incubated for 24 hours at 37°C.  After 24 
hours, gels were rinsed with 1xPBS overnight and exposed to UV light during this time. 
The following day, gels were rinsed in EGM for 3-2 hour segments, and exposed to UV 
during that time as well.  Subsequently, collagen gels were formed on top of the dECM 
hydrogels. Briefly, 0.5 mls of 10X M199 Media (With Hanks salts; Thermo Fisher) was 
added to 4 mls of collagen solution. The solution pH was then adjusted to 7.2 - 7.6 through 
the addition of 0.1M NaOH, as needed. Approximately 166.6 µls of each GF (VEGF, 
PDGF, Ang1) at a concentration of 1000 ng/ml (in sterile water) were added into the 
solution. In the control gels, sterile water was added in the place of the GFs. Solutions 
were placed in 37°C for one hour to allow for collagen to crosslink. P3-5 HUVECs were 
serum starved (0.5%) for 4 hours prior to seeding on collagen gels with or without GFs 
encapsulated within them. Cells were seeded at 40,000 cells per cm2 dependent on the 
culture dish used. After 3, 7, 14, and 21 days post cell seeding, gels were collected and 
fixed with 4% Paraformaldehyde for 15 minutes. Samples were either stored overnight at 
 
 93 
37°C or immediately stained. Cells were washed 3x for 5 minutes in 1X PBS after fixation, 
and subsequently permeabilized for 15 minutes with 0.1% Triton in 1X PBS. Cells were 
then stained with Fluoresein Phalloidin for 25 minutes, washed, and then DAPI for 10 
minutes and one final wash step. Gels were inverted onto a microscope slide and images 
on a Zeiss Meta Confocal microscope. Z stacks were taken to allow for quantification of 
invasion to the scaffold.  
 
3.4.9 Statistical Analysis  
The statistical analysis of all data was performed using GraphPad Prism 7 (GraphPad 
Software Inc, La Jolla, CA, USA). Data are presented as mean ± standard deviation unless 
otherwise stated. Statistical comparison between groups were performed using either a 
one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test (Cell 
invasion into the collagen gels, Cdc42 activation, dECM hydrogel cell invasion distance) 
or a unpaired students T-test (all other studies). p values less than or equal to 0.05 were 
considered statistically significant. 
 
3.5 Results 
3.5.1 Hydroxyproline Release Assay  
In order to fully replicate the degradation of collagen by the cells, the time it took for the 
cells to be established on the matrix had to be identified. Three different time points were  
examined, 2 hours, 4 hours, and 6 hours post the simulated cell seeding time to add the 







begin degrading the matrix. As seen in figure 3.3 the differing time addition of the 
collagenase made a significant difference in the release of hydroxyproline. Since the data 
showed that the delayed addition of the collagenase by two hours (blue) was the most 
similar to the hydroxyproline content detected by the cells seeded onto the GF containing 
gels. The 2-hour delayed collagenase time point was chosen as the in vitro model to further 
confirm the release of hydroxyproline from the cells.  
 

























Figure 3.3: Hydroxyproline Time Comparison Release. Collagenase was added on 
2, 4, or 6 hours after simulated post cell seeding time. The delay of the collagenase 
by 2 hours seemed to closely mimic the hydroxyproline release by the cells. Data 







As seen in Figure 3.4 the production of hydroxproline via the degradation of the collagen 
by either the cells or the type 1 collagenase was almost identical throughout the time 
course of the release. Therefore, the addition of type 1 collagenase after 2 hours from the 
initial set time post cell seeding was chosen to proceed forward as the in vitro model of GF 
release.  
 
3.5.2 Growth Factor Release Quantification 
The release of the three growth factors VEGF, PDGF, and Ang1 were quantified over 22 
days. This was completed to simulate the amount of time that the endothelial cells would 
be cultured in a decellularized environment. In Figure 3.5, the release is shown to first 
Figure 3.4: 2 hour Collagenase Delay- Hydroxyproline Assay. Comparison of 
hydroxyproline release over a time period of 7 days. Detection of 
hydroxyproline was almost identical between the collagenase and cell groups. 
Data represent mean +/- SD. N=6 for each timepoint 





























happen in VEGF, were sustained release of VEGF is seen, and followed by PDGF 1 day 







3.5.3 HUVEC Invasion into the Scaffold  
During the first 7 days there was no statistically significant difference between the invasion 
into the collagen gels between the GF and control groups (Figure 3.6). After 7 days 
however, there was a statistically significant difference seen. By 21 days, few or no cells 
were visible within the control gels, but cells and tubules were present in the gels with GFs 
within them (Figure 3.6). 
 
























Cumulative Growth Factor Release
Figure 3.5: Cumulative GF Release. VEGF is released initially, and release is 
sustained over the entire time period. After 2 days PDGF release is initiated. After a 
period of 7 days Ang1 is released. Data represent mean +/- SD per group and 







3.5.4 Activation of Endothelial Cell Lumen Formation Complex  
The activation of MMP14 was not seen to be different over time in the scaffold. There was 
no change of between the control and the test group (Figure 3.7). A downstream effector of 
MMP14, CDC42 a rho-GTPase, was only detected on the first 2 days post cell seeding. On 






























































Figure 3.6: Invasion Distance into Collagen. Distance HUVECs invade into collagen 
scaffolds with GFS (A), and without (B). Data represent mean +/- SD. N=6 for each group 






















Figure 3.7: Activation of MMP14/MT1MMP. No difference was seen in between the 
collagen gels containing growth factors vs control gels. Data represent mean +/- SD. 
 
 98 
the control gels (Figure 3.8). Rac1, another downstream effector of MMP14 was detected  
all throughout culture. Interestingly, on day 5 Rac1 activation was activated more than the 
control gels. Over time however, there was an increase in the activation of Rac1 on days 11 
and 14 (Figure 3.9).  
 
Figure 3.9: Activation of Rac1. No statistically significant differences seen until day 5, 
when rac1 activation increased in GF containing gels. From day 9 on, Rac1 activation was 
higher in control gels. Data represent mean +/- SD. N=3 for each group at each timepoint. 


































Figure 3.8: Activation of Cdc42. On Day 2 there was a statistically 
significant difference between the control and the GF groups. Data 
represent mean +/- SD. N=3 for each group. *= p<0.05. Statistics 































3.5.5 Modeling Decellularized Environment Using dECM Hydrogels  
In order to model how cells would behave to this system in a decellularized extracellular 
matrix environment, dECM hydrogels were utilized. The cells were either encapsulated 
within the gels, or on top.  Over a period of 14 days, there was no statistically significant 
difference seen between the cells that had been seeded on top of collagen gels with GFs vs 
the controls (Figure 3.10). However, there was a significant difference seen in cells that 












Figure 3.10: Cells on top- Invasion into the dECM. Invasion into the dECM by the endothelial cells 
over a time course of 14 days. Cells that had been seeded on top of collagen gels with GFs invaded 
into the dECM hydrogels the same statistically as their control Counter parts. Data represent 









































In tissue engineering, insufficient vascularization continues to be one of the leading 
challenges of the field. Due to oxygen’s limited diffusion capacity of ~100-200 µM, 
metabolically active tissues must have a dense microvascular supply. Synthetic or biologic 
scaffolding is used in tissue engineering as a surface for cells to grow on. These scaffolds, 
typically hydrogels, may be either pre-vascularized with cells within them, or acellular 
with modifications to the scaffold so that it encourages vascular growth into the scaffold 
itself. Some of the modifications that have been done include encapsulation of bioactive 
cues, chemical surface modification of scaffolds, and actual physical binding of bioactive 
Figure 3.11: Cells Encapsulated- Invasion into the dECM. Invasion into the dECM by the endothelial 
cells over a time course of 14 days.  After 3 days cells that had been seeded in collagen gels with GFs 
invaded into the dECM hydrogels at a distance greater than their control counterparts. By day 14 this 




cues to the scaffolds [244, 245]. The goal regardless of what method is used is to 
encourage angiogenesis, the outgrowth of new vasculature from existing vasculature, either 
into the scaffold, or if the scaffold is prevascularized, engraft with the host’s vasculature. 
While researchers have thoroughly explored ways to encourage vascular growth into the 
scaffold, few utilize methods to fully recapitulate in vivo angiogenesis.  
 
Angiogenesis is regulated by a complex series of cellular events and growth factors. The 
basic steps include degradation of the basement membrane, endothelial cell proliferation, 
migration of endothelial cells, tube formation, vessel fusion and pruning, and stabilization 
[246]. The initial migration of the endothelial cells is guided by vascular endothelial 
growth factor A (VEGF-A), as the cells migrate towards this potent stimulus. As more and 
more cells migrate towards this stimulus and proliferate, vacuoles between to develop 
within the cells and coalesce to form a lumen [246]. Various intra and extracellular 
machineries regulate this lumen formation including MT1-MMP (MMP1) and surface 
integrin’s [235]. Finally, maturation and stabilization of the lumens and nearby vessels 
coalesce to form one tube. These final processes are facilitates by growth factors such as 
PDGF-ββ and Angiopoietin 1 [242, 243]. All together, angiogenesis is an incredibly 
complex set of events that occur regularly in vivo. In tissue engineering recapitulating this 
entire cascade of signaling cascades would be difficult and complex to achieve. However, 
by choosing certain key aspects of the signaling processes, it becomes a less murky goal. 
Here, in this study, I combined three vascular growth factors, known to be important in 




In this study, I was able to create a system in which the three GFs chosen were released in 
a manner that was similar to angiogenesis in vivo. As seen in figure 3.3, release of the GFs 
occurred in a sequential order; first VEGF was released, then PDGF- ββ and finally seven 
days later Ang1, similar to the normal angiogenic events. The release that occurred was 
due to charge and size of the actual molecules. VEGF-A, is a positively charge growth 
factor that has a molecular weight of 27 kDa. PDGF-ββ is also positively charged and 
weights 25.4 kDa. Ang1 has a neutral charge, and weights 72 kDa. As collagen is a 
negatively charged protein, the charge interactions of VEGF-A and PDGF-ββ are 
suspected to have been a major predictor of their release behavior. For Ang1, due to the 
neutral charge, the size most likely determined the release rate.  
 
The endothelial cells response to the release of the growth factors was positive when 
compared to controls. The presence of the GFs increased the migration into the scaffold 
and also increased cell survival. In order this system was indeed recapitulating crucial 
angiogenic events such as lumen formation, machinery involved in the process was 
examined. Activity of MT1-MMP/MMP14 a matrix metalloproteinase known for its role 
in lumen formation was examined, and was seen that over the course of 14 days no 
significant difference was seen in the amount of activation compared to control gels. 
Initially, it was believed that the scaffold with the GFs encapsulated within them would 
increase the activation of the matrix metalloproteinase. However, it was concluded that 
although there was increased migration and cell survival, the GFs were not aberrantly 
affecting the lumen formation process, in fact, levels of activation was almost identical to 
controls (Figure 3.7). MT1-MMP/MMP14 activates downstream intracellular signaling 
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processes that are also implicated in their roles for lumen formation, such as Cdc42, a rho-
GTPase. Cdc42 is also activated by VEGF-A, and known to further activate downstream 
effectors such as Rac1, and cause actin cytoskeletal rearrangement and cell polarity 
changes [235, 247]. Cdc42 activity was measured as well. Interestingly, it was found that 
Cdc 42 was only detectable on the first 2 days of culture in cells seeded on collagen gels 
with GFs (Figure 3.8), and was significantly higher than control gels without GFs. This 
initial activation was attributed to the point in time when cells are the most motile, and first 
exposed to the GFs in high amounts, especially VEGF-A. Rac1, another lumen formation 
complex known constituent also known for cytoskeletal rearrangement was seen to be 
activated at levels similar to controls until day 5, when GF gels showed much higher 
activation compared to controls. However, as time progressed such as day 11 and 14, 
control gels actually showed higher rates of activation. This was attributed to the pro-
maturation GFs that were being released at high rates in the GF gels, known for their role 
in stopping cell migration. I was able to prove that we were not negatively affecting lumen 
formation machinery by the release of the GFs.  
 
After confirmation that the system positively influence cell behavior the system had to be 
tested within a model dECM environment. By using a dECM hydrogel system, I could 
simulate the environment that the encapsulated GFs in collagen and endothelial cells 
would be exposed to when this system would be later on used in a decellularized scaffold. 
When the cells were encapsulated within the collagen system with GFs and then this was 
seeded on top of a dECM hydrogel, migration into the matrix was significantly higher over 
the first 7 days. By day 14, the invasion into the matrix was the same compared to the 
 
 104 
control (Figure 3.10). When cells were seeded on top of the collagen gels with or without 
GFs encapsulated within them that had then been seeded on top of dECM hydrogels, 
invasion into the matrix was not statistically different (Figure 3.11). This was attributed to 
the positive affect that encapsulating cells within a hydrogel during their sol-gel transition 
has on cell survival and behavior, as well as proximity and exposure to GFs within the 
hydrogels. dECM hydrogels themselves retain extracellular matrix proteins and growth 
factors similar to in vivo and acts as a potent migration stimulator itself [93]. Further 
studies into whether cells should be encapsulated within the collagen hydrogels or seeded 




The intent of this design was to recapitulate angiogenic-signaling events that occur in vivo. 
Not only was the system that was created able to do that, it also positively increased cell 
migration into the matrix. The system was also shown to not effect angiogenic processes in 
a negative manner, instead increasing activation of lumen formation complex machinery 
such as Cdc42, without which, has shown to inhibit endothelial cell lumen formation 
[239]. This collagen encapsulated growth factor system was created for use within 
decellularized scaffolds to help encourage microvascular growth and overall cell coverage 
within these scaffolds. By utilizing a 3D dECM hydrogel to model a decellularized 
environment, I showed that the encapsulation of ECs within collagen that has GFs 
encapsulated within it encourages migration into the dECM. The exciting results indicate 
that this system may be beneficial and help encourage microvascular growth within 
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decellularized specimens. Further studies into the utilization of the system in an actual 
scaffold within lumens of a decellularized matrix should be completed to fully elucidate 

























4.1 Angiogenic Growth Factors Encourage Vascularization in dECM  
As human life expectancy continues to increase with newer technologies aimed at keeping 
the population healthier longer, age related diseases and trauma to internal organs 
increases. When damage from the previously mentioned diseases occur that is severe 
enough, a transplant may be necessitated. Currently, across all donor organ waiting lists, 
the list for those awaiting transplant far exceeds the availble donor organs. Over time 
donor organ availability has plateued, while those needing a transplant has continued to 
exponentially grow [248] (Figure 4.1). To alleviate this apparent discrepency alternatives 




















































































Figure 4.1: Transplant Donors, Waiting List, and Recipients. Data taken from OPTN.org.  
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Regenerative medicine is a broad field of study whose main goal is to either replace or 
repair damaged tissues. This damage may arise from congenital defects, trauma, or age 
related diseases. In order to accomplish this goal of replacing damaged tissue, a scaffold is 
most often used as a method to either replace a piece of damaged tissue, either delivered 
acellular or seeded with cells. This scaffolding is used as a physical mechanical support to 
the tissue, or as a method of delivering bioactive cues that can stimulate repair, or act as a  
delivery method for new cells to repopulate a damaged area. The scaffolding chose 
however, must be able to recapitulate the tissue that is to be replaced both mechanically, 
and environmentally. Biomaterials used as a scaffolding may be either syntheic and 
biologic in origin, but few can fully mimic the complex in vivo environment. 
Decellularized organs have emerged as a new scaffold, where a cadaveric organ’s own 
cells are removed leaving the extracellular matrix behind. However, as noted in Chapter 
1b, the microvasculature is also removed. This renders decellularized organs an almost 
perfect choice as a replacement organ, but still not completely ideal. There are however, 
methods to encourage vascularization of these scaffolds as mentioned in Chapter 1b. 
Because of the significant need to vascularize decellularized scaffolds at a faster rate, I 
decided to focus my research on a method to increase the vascularization of said scaffolds 
by delivery angiogenic growth factors to the scaffold.  
 
The first step was working on the model environment that would be used as a subsitute for 
the decellularized scaffold. Since the use of a full acellular organ scaffold was beyond the 
scope of the work described here, a smaller in vitro model system needed to be utilized. In 
chapter 2, I used a known cardiac decellularized extracellular matrix protocol, and added a 
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crosslinker in to create more mechanically stiff gels. Without the addition of the 
crosslinker, genipin, the gels would be virtually impossible to handle and not an ideal 
model system. Upon further research into the literature, it was discovered that the protocol 
to actually make these hydrogels was somewhat customizable for the desired application. 
In one of the processeing steps, the dECM is digested in a pepsin and HCl solution. 
Throughout the literature, there is not a consensus over the length of time utilized for this 
step. Should it be until the tissue is solubilized? Or does it need to be longer? Curious 
about this, I decided to dive deeper into whether a specific digestion time would actually 
affect cell behavior and material strength. As time progresses, the protein fragments in the 
solution should become smaller, and theoretically this should affect the final hydrogel 
characteristics because of the smaller peptide pieces that are then being recrosslinked 
together. The final hydrogel of a dECM solution that had been digested longer than a 
solution that had been digested for a shorter amount of time, should be a completely 
different environment for the cells. It would follow then, that this difference in cell 
microenvironment would then affect cell behavior such as differentiation. Following 
previously completed research, hADSCs were chosen as a stem cell model system since 
they have been previously shown to differentiate towards cardiac lineages on cardiac 
hydrogels. To test this further, β4 and  β5 integrins were blocked on cell surfaces. This was 
done to elucidate whether this different material composition was indeed affecting cell 
differentiation, and were chosen based on their roles in recognition of known cardiac 
differntiation influencers Laminin and Fibronectin. The hypothesis was that these would 
show us the significance of the different protein profiles. Because of the different laminin 
and fibronectin amounts that was seen on the Mass Spec data, I further was interested in 
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this. Upon first experimentation, it was found that the blocking of these integrins actually 
led to an upregulation of certain cardiac genes when compared to collagen controls. A 
further dive into the literature revealed that the previous work has shown that blocking of 
beta 5 integrin actually has led to an upregluation of beta 1 integrin signaling [212]. 
Because of the importance of beta 1 integrin to cardiac differentiation, I then hypothesized 
that this cardiac gene expression upregulation was attributable to the increase in the beta 1 
integrin signaling activity. The beta 1 integrin activity was analyzed using an antibody that 
detects active beta 1 integrin, HUTS4, and was shown to be active more in the integrin 
blocked groups, than their control counterparts. This data gave us evidence of not only the 
importance of beta 1 integrin signalling in cardiac development, but also how cardiac 
differentiation can be potentially upregulated.  
 
4.2 New Methods to Vascularize Acellular Cardiac Scaffolds  
In acellular cardiac scaffolds re-endothelialization of the scaffolds is impertive for their 
therapeutic use. First, full coverage of the ECM is required in order to prevent thrombosis 
from occuring. Second, the endothelial cells must be able to migrate out of the higher order 
vascular conduit branchs, and form microvasculature (Figure 4.2). In my research, after the 
model decellularized environment was successfully made and characterized, attention was 
then turned to making the growth factor delivery vehicle. Because of the short half-life of 
most bioactive molecules, bolus delivery methods are not optimial. Therefore, 





porcine collagen as it is the most abundant in the cardiac matrix and is easily accessible I 
chose known angiogenic growth factors VEGF-A, PDGF-BB, and Ang1, to be released 
from the scaffold based on charge and size. In chapter 3, I characterized the release of 
these growth factors from collagenous scaffolds over the course of 22 days. In 
recellularization of cardiac scaffolds, the time to re-endothelialze the scaffold is typically 
~14 days, which was the intended time course of the experiment. I found that the release of 
the growth factors was similar to what the timecourse of release is in vivo. By mimicing 
angiogenic signaling cascades, the system is attempting to create a environment similar to 
in vivo with the desire of causing correct cell behavior and microvascular growth. I made 
sure to ensure that critical angiogenesis machinery such as the endothelial cell lumen 
formation complex was not abbherently affecting this. The endothelial cell lumen 
formation complex is responsible for the beginning stages of vessel formation, specifically 
Figure 4.2: New Vascular Growth in a Decellularized Scaffold. Representation of new 
vasculature growing out of existing vasculature in acellular cardiac scaffold. Red- 
Exsisting vasculature, and Green- New vasculature outgrowth. 
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when the endothelial cells are colaescing with another endothelial cell outgrowth from 
another area in the body to form a microvasculature. If this process did not work correctly, 
no fluid would be able to travel through, it would essentially act as a plug.  
 
In acellular cardiac scaffolds re-endothelialization of the scaffolds is impertive for their 
use. As mentioned previously, naked vascular conduits cause thrombosis when blood 
makes contact with those surfaces [62]. Therefore the inclusion of potent cell growth 
bioactive molecules such as VEGF-A is crucial. Because of this fact, and the main end 
goal of having microvascular outgrowth out of the exisisting larger order vascular 
conduits, migration through either the collagen or dECM hydrogels were a critical 
endpoint. In Chapter 3, I examined the invasion of the cells into both the collagenous 
scaffolds and the collagen scaffolds that had been made on top of the dECM hydrogels.  
 I found that the cells that had been encapsulated within the top collagen gels with growth 
factors invaded into the dECM hydrogel that was on bottom, more than the their non GF 
counterparts (Figure 3.11, Figure 4.3). The reason why it was tested against it’s non 
growth factor counterparts is that the dECM itself should be a potent mitogen, as the ECM 
is full of bioactive cues. It showed evidence that the presence of the growth factors helped 
increase the migratory behahavior of the endothelial cells- a critical endpoint for these 
studies. This gave us the crucial evidence that the presence of the GFs would not only help 










The central goal of this dissertation was to deliver growth factors to a cardiac 
decellularized extracellular matrix environment to increase microvascular growth. In order 
to mimic the complex cardiac decellularized matrix environment, in chapter 2 I developed 
a cardiac hydrogel system crosslinked with a low-cytotoxic crosslinker genipin, and 
examined the material characteristics. I showed that the digestion time of the dECM in the 
enzyme pepsin affected the final material characteristics, and also influenced cell behavior. 
First, I showed that gelation of the dECM, or the time it takes for the material to form a 
gel, was the lowest when the dECM had been digested the least amount of time. 
Additionally, I showed that the degradation kinetics was affected by the digestion time, as 
dECM that had been digested for the least amount of time took the most time to degrade.  
Figure 4.3: Cells Encapsulated- Invasion into the dECM Images. Endothelial cells ecapsulated within 
collagen gels with GFs (right) and without GFs (left), that were seeded on top of dECM hydrogels. Green- 
Actin, Blue, Dapi, Red, auto fluorescence from Genipin hydrogels  
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Finally, the storage modulus was also affected my the digestion length, with the second 
longest digestion time showing the highest material strength.  
 
In the rest of chapter 2, I delved into how the digestion length affected the differentiation 
of the hADSCs towards a cardiomyocyte lineage. I showed that the least digestion time led 
to a increase in cardiac phenotypic genes, more than likely due to a environement that is 
more similar to in vivo. To follow that up and examine whether certain proteins were 
influencing the differentiation, two integrins β4 and β5 were blocked and shown to cause 
an even further upregulation of cardiac phenotypic genes. This was hypothesized to be 
attributed to the integrin crosstalk and increased activity of a known cardiac influencing 
integrin- β1.  
 
In chapter 3, I show that the combination of three angiogenic growth factors (VEGF-A, 
PDGF- ββ, and Ang1) in a collagen hydrogel release in a fashion that mimics the natural 
angiogenic cascade of events. Further, this release of growth factors encourages cell 
migration and invasion into the collagen scaffold- a critical endpoint. Additionally, in 
chapter 3 I show that the EC lumen formation complex, crucial for the formation of 
functional vasculature, was not damaged or downregulated by the addition of the GFs. Cdc 
42, a rho-GTPase component of the lumen formation complex was shown to be 
upregulated compared to our control gels without GFs within them, and was attributed to 
the release of the VEGF-A intially. Collectively, the data presented in chapter 3 show 
evidence that the combination of the three GFs positively influence endothelial cells and 
encourage neovascularization behavior. Finally in chapter 3, I combined the dECM 
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hydrogel that I had developed from chapter 2 with my collagen containing GF system and 
examined the invasion of cells into the scaffold. I found that the cells encapsulated within 
the collagen hydrogels with GFs will be the most optimal condition to proceed with further 
research. In this condition, cells invaded into the matrix deeper compared to controls. 
Overall, the work done here establishes the first ever study into how decellularized cardiac 
extracellular matrix hydrogel digestion affects material behavior and also how that change 
in behavior influences both parenchymal and stem cells. Additionally, the work done here 
establishes a model to be used that may increase the vascularization in decellularized 
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